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ABSTRACT 
 





In this study, we investigated the mechanisms by which PBRM1 functions as a tumor suppressor 
in clear cell renal cell carcinoma.  PBRM1, also known as BAF180 or Polybromo, is a member of the 
PBAF SWI/SNF chromatin remodeling complex.  Cancer sequencing studies have revealed that SWI/SNF 
components are widely mutated in cancer.  PBRM1 is recurrently mutated in various human 
malignancies, but it has a particularly high mutation rate in clear cell renal cell carcinoma: ~40% of clear 
cell renal cell carcinomas have a PBRM1 mutation, making it the second most highly mutated gene in 
clear cell renal cell carcinoma behind VHL.  Although many recent studies have looked at how other 
SWI/SNF components function in cancer control, relatively little is known about the tumor suppressive 
mechanisms of PBRM1 in clear cell renal cell carcinoma. 
To investigate PBRM1 function, we manipulated its expression in clear cell renal cell carcinoma 
cell lines.  In cell lines with intact PBRM1, we stably knocked down its expression using shRNA.  In a cell 
line with mutant PBRM1, we stably restored expression of the wild-type protein.  We found that PBRM1 
deficiency significantly enhanced the growth properties of cells, but only when the cells were grown under 
stressful conditions, such as reduced serum or a 3-D culture environment.  To investigate genes and 
pathways influenced by PBRM1 that may confer this growth advantage, we compared gene expression 
differences in the clear cell renal cell carcinoma cell lines and murine embryonic fibroblasts with or without 
PBRM1.  We found that PBRM1 regulated numerous cancer-related genes and pathways. 
One gene, ALDH1A1, was consistently upregulated with PBRM1 deficiency across our cell lines.  
Further expression analysis using two different clear cell renal cell carcinoma primary tumor datasets 
revealed that PBRM1 mutation in primary tumors was also associated with higher ALDH1A1 levels. 
ALDH1A1, or aldehyde dehydrogenase 1, is part of the retinoic acid metabolic pathway and irreversibly 
converts retinaldehyde to retinoic acid.  It functions in hematopoietic stem cell development, white versus 
brown fat programming, and insulin signaling.  Numerous studies have also identified ALDH1A1 as a 
marker of tumor-initiating cells, also known as cancer stem cells.  Not much is known about the regulation 
of ALDH1A1 expression in cancer, and it has not previously been linked to PBRM1 or SWI/SNF.  We 
confirmed that stable knockdown of PBRM1 in clear cell renal cell carcinoma cell lines resulted in higher 
ALDH1A1 mRNA and protein expression, and also higher ALDH1-class enzyme activity.  Alternatively, re-
expression of wild-type PBRM1, but not cancer-associated mutant PBRM1, lowered ALDH1A1 
expression and activity in the PBRM1-mutant line.  Additionally, inhibiting ALDH1A1 or knocking it down 
in the context of PBRM1 deficiency reduced anchorage-independent growth, while over-expressing 
ALDH1A1 in the PBRM1-normal setting increased tumorsphere-forming capacity.  These results suggest 
that ALDH1A1 is not only a marker of tumor-initiating cells, but can also increase the tumorigenic 
potential of cells.  
Based on our gene expression analysis, we additionally explored PBRM1 regulation of the EGFR 
and IFN pathways.  PBRM1 decreased total EGFR protein levels and dampened downstream signaling.  
These changes had functional consequences, as PBRM1 deficiency led to faster growth in response to 
EGF stimulation.  However, it did not create a setting of oncogenic addiction, as PBRM1 deficient cells 
were also more resistant to EGFR inhibition.  Alternatively, PBRM1 deficiency reduced basal and IFNα-
induced levels of IFI27, a pro-apoptotic interferon response gene, and made cells more resistant to 
growth inhibition by IFNα.  PBRM1 mutations in cancer would thus be expected to have wide-ranging 
effects on a cell, and the targeting of any one specific downstream pathway might have limited efficacy. 
Finally, we investigated the molecular mechanisms of how PBRM1 deficiency could alter 
transcription, keeping in mind that PBRM1 is one subunit of the larger PBAF complex.  In our clear cell 
renal cell carcinoma cell lines, we found that mRNA and protein levels of another PBAF-specific subunit, 
ARID2, increased with PBRM1 deficiency.  PBRM1 mutation in primary tumors was also associated with 
significantly higher ARID2 expression.  Immunoprecipitation and glycerol gradient fractionation 
experiments suggested that more ARID2 may associate with the SWI/SNF components BRG1 and SNF5 
after PBRM1 knockdown.  ARID2 ChIP-seq analysis revealed that this remnant PBAF-like complex was 
bound to fewer locations in the genome, and its binding locations were broadly redistributed.  Both gained 
and lost ARID2 binding were associated with differential gene expression, of both upregulated and 
downregulated genes, indicating that the genomic context influences whether PBAF-binding is activating 
or repressive.  Interestingly, we also found that ARID2 was required for some of the pro-tumorigenic 
changes associated with PBRM1 deficiency, such as upregulation of ALDH1A1 and EGFR levels, but not 
others, such as decreased IFI27 levels, implying alternative modes of transcriptional regulation.   
In total, this study implicates PBRM1 in the regulation of numerous cancer-related genes and 
pathways in clear cell renal cell carcinoma.  PBRM1 mutation would alter the genomic binding of a 
residual PBAF-like complex containing ARID2, leading to transcriptional changes that promote tumor 
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 In eukaryotic organisms, DNA is packaged with both histone and non-histone proteins to form 
chromatin, the basic organizing principle of the genome.  The basic unit of chromatin is the nucleosome, 
which consists of ~146 base-pairs of DNA wrapped around a histone octamer (two copies each of H2A, 
H2B, H3, and H4) (Luger et al., 2012).  Nucleosomes are connected by small fragments of “linker” DNA, 
and are organized into higher order chromatin structures.  The chromatin state of a cell, however, is 
highly dynamic, and changes in conjunction with such processes as DNA replication, repair, and 
transcription.  Chromatin state is governed by a variety of mechanisms, including DNA methylation, 
histone variant incorporation, histone post-translational modification, and ATP-dependent chromatin 
remodeling (Chen and Dent, 2014).  Among the ATP-dependent chromatin remodelers, there are four 




SWI/SNF complexes are multi-subunit chromatin remodeling complexes that alter the connection 
between DNA and the histone octamer.  Members of the SWI/SNF complex were originally identified in 
Saccharomyces cerevisiae in two independent screens for mutants affecting mating type switching 
(SWItching Defective, SWI) or growth on sucrose (Sucrose NonFermenting, SNF) (Stern et al., 1984) 
(Breeden and Nasmyth, 1987) (Neigeborn and Carlson, 1984).  Several of the identified genes were later 
found to encode proteins that associate in a large multisubunit complex that is capable of altering 
nucleosome structure in an ATP-dependent manner (Cairns et al., 1994) (Cote et al., 1994).  The 
Kornberg lab subsequently identified a similar complex in S. cerevisiae that shared some of the same 
subunits as the original complex and could also remodel chromatin in an ATP-dependent manner (Cairns 
et al., 1996).  This complex, which they termed RSC (for Remodels the Structure of Chromatin), was 
unique, however, in its high abundance and absolute requirement for viability.  Similar complexes to 
SWI/SNF and RSC were later identified in Drosophila melanogaster (bap and pbap) based on homology 
of subunits and similar biochemical activity (Tamkun et al., 1992) (Papoulas et al., 1998).  The Crabtree 
group purified the mammalian SWI/SNF complex using similar methods (Wang et al., 1996). 
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Mammalian SWI/SNF complexes consist of 12-16 subunits (Wang et al., 1996) (Kadoch et al., 
2013), which can be divided into a core complex that is capable of in vitro nucleosome remodeling, and 
accessory subunits that are thought to confer functional specificity to the complexes in vivo (Phelan, 
1999).  The core complex consists of one of two mutually exclusive ATPase domains: either BRM (for 
brahma homologue; also known as SMARCA2) or BRG1 (for BRM-related gene 1; also known as 
SMARCA4); and SNF5 (also known as SMARCAB1, INI1, or BAF47), BAF155, and BAF170.  BRG1-
containing complexes can be further divided based on their accessory subunits: ARID1A or ARID1B (also 
known as BAF250A or B) define the BAF complex (for Brg1-Associated Factors; also known as SWI/SNF-
A), while PBRM1 (also known as BAF180, Polybromo-1, or PB1), ARID2 (also known as BAF200), and 
BRD7 are found exclusively in the PBAF complex (for Polybromo Brg1-Associated Factors; also known 
as SWI/SNF-B) (Wilson and Roberts, 2011).  The mammalian BAF complex is thought to be more like the 
yeast SWI/SNF complex, while PBAF is thought to more resemble the RSC complex.  Figure 1.1 shows 
































B, or C) 
SS18 
PBAF BAF 
Figure 1.1 - Subunit composition of mSWI/SNF complexes.  BAF complexes contain one of two mutually 
exclusive ATP-dependent DNA-helicases (either BRM or BRG1), whereas the PBAF complex only contains 
BRG1. The complexes also contain accessory subunits that are thought to confer functional specificity in 
vivo, by altering where the complexes bind in the genome and what co-factors they bind.  PBRM1, along 
with ARID2 and BRD7, are the defining subunits of the PBAF complex, while ARID1A and ARID1B are 
specific to the BAF complex. 
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As chromatin remodelers, SWI/SNF complexes alter the association of DNA with histones in an 
ATP-dependent manner.  SWI/SNF nucleosome binding is thought to disrupt DNA-histone contacts and 
induce DNA translocation and loop formation (Wilson and Roberts, 2011).  Loop propagation then results 
in either nucleosome sliding or ejection of an adjacent nucleosome.  In either case, the end result is a 
more exposed portion of DNA that is now capable of binding to additional cofactors.  In yeast, SWI/SNF 
action is exclusively activating, i.e., nearby genes are transcribed more (Carlson and Laurent, 1994).  
However, in higher organisms, SWI/SNF activity can result in the activation or repression of nearby 
genes, depending on the gene and cellular context (Chi et al., 2002) (Isakoff et al., 2005).   
Specificity of action of SWI/SNF complexes is achieved through the complex combinatorial 
assembly of its subunits, many of which exist as multiple isoforms (Wu et al., 2009).  These different 
complexes can be mutually exclusive depending on the cell type and state of differentiation.  For 
example, the esBAF complex identified by the Crabtree lab is only found in embryonic stem (ES) cells 
and is essential for maintaining stem cell pluripotency and self-renewal capacity (Ho et al., 2009).  
Alternatively, other SWI/SNF complexes are necessary for the terminal differentiation of certain cell types, 
such as neurons or myocytes (Lessard et al., 2007) (Albini and Puri, 2010).   
For complexes that co-exist in a particular cell, specificity of action is thought to be achieved 
through the docking of specific transcription factors and/or complex interactions with chromatin (e.g., 
reading the “histone code”).  SWI/SNF subunits are known to associate with a variety of other factors 
involved in transcriptional control, including but not limited to histone modifying enzymes (Sif et al., 2001) 
(Kia et al., 2008) (Wilson et al., 2010), cell cycle control proteins such as RB (Dunaief et al., 1994), p53 
(Burrows et al., 2010), MYC (Romero et al., 2012), and smads (Xi et al., 2008), and nuclear hormone 
receptors (Lemon et al., 2001).  Through these interactions, SWI/SNF complexes are capable of altering 
particular transcriptional programs.  Additionally, multiple SWI/SNF subunits contain “reader” domains 
that can bind post-translational histone modifications, such as bromodomains that bind acetylated lysine 
residues and chromo-related domains that bind methylated histones.  PBRM1 contains six tandem 
bromodomains, BRG1 and BRM each have one bromodomain, and BAF155 and BAF170 each have one 
chromo-related domain (Wu et al., 2009).  These subunits may help target SWI/SNF complexes to 
specific genomic loci based on histone modification status.   
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Chromatin immunoprecipitation-sequencing (ChIP-seq) employs next generation sequencing to 
determine where a protein is binding in the genome at high resolution, and has previously been employed 
to study some SWI/SNF subunits.  The Crabtree group performed ChIP-seq on BRG1 in ES cells to see 
where the esBAF complex was binding (Ho et al., 2009).  They found that the complex was most highly 
enriched at transcriptional start sites (TSS), and was playing roles in both gene activation and repression.  
Interestingly, they concluded that esBAF played more of a repressive role to fine-tune the levels of key 
ES-specific genes and prevent their overexpression, which would lead to perturbation of the pluripotency 
circuitry and eventual differentiation.  A 2011 ChIP-seq study investigating where the core SWI/SNF 
constituents (BRG1, BAF155, BAF170, and SNF5) bind in HeLa cells supported some of the same 
conclusions: SWI/SNF binds to TSS and mediates both gene activation and repression (Euskirchen et al., 
2011).  This study also found high enrichment at enhancer sites, suggesting SWI/SNF involvement in 
long-range gene regulation, and that some SWI/SNF subunits may assemble in preliminary configurations 
and wait poised on gene regulatory elements to receive the rest of the complex.  This intriguing 
conclusion is supported by another study in D. melanogaster that found that the SWI/SNF complexes bap 
and pbap function as holoenzymes, in which the core complex can assemble on its own on the genome 
but cannot participate in transcriptional control in vivo without the complex-specific subunits, such as 
polybromo (the fly orthologue of PBRM1) (Moshkin et al., 2007). 
 
SWI/SNF and cancer 
It is now recognized that SWI/SNF subunits are widely mutated in human malignancies.  Indeed, 
surveys of recent cancer exome sequencing studies indicate that SWI/SNF components are mutated in 
~20% of all cancers (Kadoch et al., 2013) (Shain and Pollack, 2013).  SNF5 was the first SWI/SNF 
subunit implicated as a tumor suppressor.  Nearly all malignant rhabdoid tumors, a very aggressive 
pediatric cancer associated with tumors in the brain, kidney, and soft tissue, are associated with biallelic 
loss of SNF5 (Versteege et al., 1998).  It is thought that these tumors have very few cancer-associated 
mutations, and in some cases, SNF5 mutation is the only detectable somatic mutation (McKenna et al., 
2008) (Lee et al., 2012).  Conditional knockout of SNF5 in mouse models leads to fully penetrant 
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lymphomas and rhabdoid tumors with a median onset of 11 weeks, an incredibly rapid timeframe 
(Roberts et al., 2002).   
Other SWI/SNF subunits are mutated across a variety of other malignancies (Helming et al., 
2014a).  For example, BRG1 expression is absent in 15-50% of primary human non-small cell lung 
cancer samples, and mutations are frequently seen in a variety of lung cancer cell lines (Reisman et al., 
2003) (Medina et al., 2008).  BRG1 is also mutated in medulloblastoma (Parsons et al., 2011), 11% of 
esophageal adenocarcinomas (Dulak et al., 2013), and to a lesser extent in melanoma and pancreatic 
ductal adenocarcinoma (PDA) (Shain and Pollack, 2013).  Additionally, it was recently discovered that 
BRG1 is mutated and protein expression is lost in practically all cases of small cell carcinoma of the 
ovary, hypercalcemic type, a rare, very aggressive form of ovarian cancer primarily diagnosed in young 
women (Witkowski et al., 2014) (Jelinic et al., 2014) (Ramos et al., 2014). 
The “targeting” subunits of the complex are also highly involved in cancer.  The BAF-specific 
subunit ARID1A is mutated in 50% of ovarian clear cell carcinomas, a highly lethal subtype (Jones et al., 
2010).  It is also mutated in 30% of endometrioid tumors (Wiegand et al., 2010), and to a lesser extent in 
multiple other cancers, including 14% of intrahepatic cholangiocarcinomas (Jiao et al., 2013), ~10% of 
esophageal adenocarcinomas (Dulak et al., 2013), ~8% of gastric adenocarcinomas (Zang et al., 2012), 
and a small percentage of PDA (Biankin et al., 2012).  Meanwhile, PBAF-specific ARID2 is mutated in 
~18% of hepatitis C-associated hepatocellular carcinomas (Li et al., 2011), ~9% of melanomas (Hodis et 
al., 2012), and a small percentage of PDA (Biankin et al., 2012).   
The other PBAF-specific subunit, PBRM1, is also mutated in human malignancies.  In a 2008 
study, the Parsons lab used representational difference analysis to identify candidate tumor suppressor 
genes by looking for chromosomal regions that are homozygously deleted in the breast cancer cell line 
HCC1143 (Xia et al., 2008).  This approach revealed a 70 kilobase deletion at chromosomal location 
3p21 that encodes exons 12-22 of PBRM1.  Screening of breast cancer cell lines and primary tumors 
identified three other PBRM1 truncation mutations (~4% primary tumors and cell lines were mutated).  In 
a 2011 study, exome sequencing of seven cases of clear cell renal cell carcinoma (ccRCC) identified four 
homozygous truncating mutations in the PBRM1 gene (Varela et al., 2011).  Confirmatory analysis of 227 
primary ccRCC samples revealed PBRM1 mutations in 41% of the cases.  Moreover, in this same study, 
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analysis of data from a forward genetic screen using a conditional Sleeping Beauty transposon system 
looking for drivers of PDA in a KrasG12D mouse model revealed significant enrichment of insertion sites in 
PBRM1, across multiple stages of pancreatic cancer.  Another study identified structural mutations 
converging on SWI/SNF subunits, including PBRM1, in a PDA panel using high-resolution genomic 
profiling and mutational data (Shain et al., 2012).  Overall, aberrant SWI/SNF subunits were present in 
34% of samples tested, suggesting a significant role for SWI/SNF activity in pancreatic tumorigenesis.  
Additionally, the same study that identified recurrent ARID1A mutations in intrahepatic 
cholangiocarcinomas also detected PBRM1 mutations in 13% of cases and 25% of gallbladder 
carcinomas (Jiao et al., 2013).  Studies from the Cancer Genome Atlas (TCGA) have found similar 
PBRM1 mutations rates in these cancers, along with identifying new malignancies with recurrent PBRM1 
mutations, such as bladder urothelial carcinoma (9%) and stomach adenocarcinoma (7%) (Cancer 
Genome Atlas Research, 2014b) (Cancer Genome Atlas Research, 2014a).  The mutation frequency of 
PBRM1 across various cancers is presented in Figure 1.2, which summarizes data from 105 studies as 


























































































































































































































































































































































































































PBRM1 is a 180 kilodalton protein encoded by the PBRM1 gene located at chromosomal position 
3p21 in Homo sapiens.  As shown in Figure 1.3, it consists of six tandem bromodomains, two tandem 
bromo-adjacent homology (BAH) domains, a DNA-binding high mobility group (HMG) domain, and two 
LXXLL hormone recognition motifs.  The bromodomains are capable of binding to acetylated lysine 
residues, such as those found on histone tails (Chandrasekaran and Thompson, 2007).  It is the only 
protein found in humans with this many bromodomains.  Although the exact function of the BAH domains 
is unknown, histone acetylation at H4K16 and tri-methylation at H3K79 have been implicated as key 
regulators of BAH-domain containing protein activity (Armache et al., 2011).  Based on its functional 
domain composition, PBRM1 is thought to represent the combination of three individual components of 
the yeast RSC complex: Rsc1, Rsc2, and Rsc4 (Xue et al., 2000).  Human PBRM1 shares 50% amino 
acid similarity with Drosophila melanogaster and 92% similarity with Mus musculus.  It was identified by 
the Crabtree lab in a screen for the mammalian homologues of yeast SWI/SNF, and is one of the defining 









Known roles of PBRM1 in tumor suppression 
Studies of PBRM1 function in lower organisms may provide valuable insights into PBRM1 tumor 
suppression in mammals.  In yeast, the RSC complex is involved in transcriptional regulation, DNA repair 
(Kent et al., 2007) (Shim et al., 2007), chromatid cohesion (Gartenberg, 2009), and kinetochore formation 
(Desai et al., 2009).  In D. melanogaster, the pbap complex has been found to antagonize the EGFR 
pathway.  In one study, the authors looked at pbap-specific functions by focusing on bap170 (the fly 
PBRM1 Isoform 2 (AAG48933.1), form most expressed in breast/renal epithelia 
Figure 1.3 - The structure of PBRM1.  PBRM1 consists of 6 tandem bromodomains, which bind to 
acetylated lysine residues, 2 BAH domains, and a DNA-binding HMG domain. It also contains the two 
indicated LXXLL hormone recognition motifs.  Selected cancer missense mutations are indicated in red. 
10 
 
orthologue of ARID2) (Rendina et al., 2010).  They found a genetic interaction between bap170 and 
signaling components of the EGFR pathway, and concluded that bap170 negatively regulated the EGFR 
pathway through the repression of rhomboid and activation of argos.  The authors did not explore whether 
these findings also translated to polybromo (the fly orthologue of PBRM1).  In another study, the authors 
used a temperature-sensitive snr1-mutant (the fly orthologue of human SNF5) that produced wing 
patterning phenotypes to conduct an unbiased genetic modifier screen to look for SWI/SNF target genes 
and cofactors (Curtis et al., 2011). Components of the EGFR, Notch, and DPP pathways were identified 
as gene targets, and epistasis experiments revealed a connection between pbap (but not bap) and the 
histone demethylase lsd1 as co-repressors of these pathways.  Other studies have linked pbap to 
regulation of genes involved in tissue remodeling and immune function (Carrera et al., 2008), and 
polybromo has also been found to be required for histone H3.3 replacement at chromatin boundaries, a 
key event in cellular memory (Nakayama et al., 2012). 
In mice, the effects of global loss of Pbrm1 have been examined (Wang et al., 2004).  Pbrm1 
knockout mice displayed severe hypoplastic ventricle development and trophoblast placental defects, and 
died between embryonic days 12.5-15.5.  Mice heterozygous for the loss of Pbrm1 were viable and 
appeared normal, although it is unclear whether they were followed long-term for tumor development.  
The authors noted that the defects resembled those seen for loss of RXRα and PPARγ, and they 
subsequently identified certain retinoic acid-induced genes (RARβ2 and CRABPII) that are important for 
heart development and that are aberrantly expressed with Pbrm1 loss.  This finding further supports the 
notion that the PBAF complex is involved in nuclear hormone receptor transcriptional programs (Lemon et 
al., 2001).   
Another study in mice has linked PBRM1 to the repression of IL-10 in Th2 cells (Wurster et al., 
2012).  The authors used a conditional knock-out mouse for Pbrm1 in T cells, and noted no defects in T 
cell development.  However, in the Th2 cell population, the immunoregulatory cytokine IL-10 was 
upregulated.  The authors found that Pbrm1 bound to regulatory elements of the IL-10 gene, and that 




Previous studies have also provided some clues as to how PBRM1 may function as a tumor 
suppressor.  The studies from the Parsons lab first identifying PBRM1 as a tumor suppressor indicated 
that it exerts cell cycle control through induction of p21 (Xia et al., 2008).  Restoration of PBRM1 
expression in HCC1143 cells resulted in G1 arrest induced by PBRM1 binding to the p21 promoter.  
Further, PBRM1 was critical for p21 upregulation and G1 arrest in response to TGFβ treatment or γ-
irradiation in the non-transformed breast line MCF10A.  PBRM1, along with BRD7, has also been 
identified as a vital component of p53-associated replicative senescence (Burrows et al., 2010).  In the 
2011 ccRCC exome sequencing study, knockdown of PBRM1 in ccRCC cell lines with wild-type PBRM1 
led to increased proliferation, growth in soft agar, and migration (Varela et al., 2011).  Gene set 
enrichment analysis of microarray data from these knockdown experiments supported PBRM1’s role in 
cell cycle control, and also associated it with chromosomal stability.  This is in agreement with findings 
from the initial study identifying the PBAF complex – the authors reported that the PBAF complex 
localized to kinetochores during mitosis (Xue et al., 2000).   
Two more recent studies have further supported PBRM1’s role in maintaining genome integrity.  
In the first study, the authors found that PBRM1 was important for sister chromatid centromeric cohesion 
in mouse embryonic stem cells, human fibroblasts, and an osteosarcoma cell line, and that siRNA 
knockdown of PBRM1 or expression of PBRM1 cancer-associated missense mutations led to 
chromosomal instability (Brownlee et al., 2014).  The same group also reported that PBRM1 is required 
for transcriptional silencing and subsequent DNA repair at early time points at a subset of DNA double-
strand breaks (Kakarougkas et al., 2014).  Interestingly, the authors suggest that this process is 
dependent on ATM phosphorylation of PBRM1, and that PBAF-chromatin remodeling activity may act 
downstream of ATM to help promote H2AK119 monoubiquitination and double-strand break repair. 
The structure of PBRM1 provides additional clues regarding its function.  As mentioned above, its 
six tandem bromodomains can bind acetylated lysine residues, and thus may help target the PBAF 
complex to specific genomic locations based on histone modifications (Chandrasekaran and Thompson, 
2007).  A study of BAH domain activity suggests the two BAH domains may be playing a similar role 
(Armache et al., 2011).  Although ChIP-seq analysis has been performed on other SWI/SNF subunits, 
there are no published reports of PBRM1 ChIP-seq showing where it binds in the genome.  PBRM1 also 
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contains two hormone recognition motifs, and the PBAF complex has been found to associate with 
multiple nuclear hormone receptors and to mediate hormone-induced transcription in vitro (Lemon et al., 
2001).  No “hotspot” mutations of PBRM1 have been identified in human cancers.  Instead, known 
PBRM1 mutations are spread across functional domains and consist of truncating nonsense mutations, 
missense mutations, and in-frame deletions/insertions (Xia et al., 2008) (Varela et al., 2011) (Shain et al., 
2012).   
The PBAF complex has also been linked to interferon signaling (Yan et al., 2005).  This study 
initially identified ARID2 as a PBAF complex member.  Looking in HeLa cells, the authors found that 
ARID2 was required for PBAF complex assembly – without it, the complex fell apart and PBRM1 was 
degraded.  However, the reverse was not true – PBRM1 knockdown did not cause a reciprocal decline in 
ARID2 levels.  In HCC1143 cells, where PBRM1 is not expressed, ARID2 was expressed and was still 
capable of associating in a complex with other SWI/SNF components.  Additionally, ARID2, but not 
PBRM1, was required for the transcription of IFITM1, an interferon-responsive gene, in response to 
interferon-α (IFNα) stimulation.  These findings suggest that a PBAF-like complex remains even after 
PBRM1 loss, and that this complex is still capable of altering transcriptional programs.   
As part of their large-scale genetic and molecular profiling of ccRCC tumors, the Cancer Genome 
Atlas consortium identified enriched gene classes in sets of differentially expressed genes between 
tumors with mutations in different ccRCC tumor suppressors (VHL, PBRM1, SETD2, and BAP1) (Cancer 
Genome Atlas Research, 2013).  Tumors with PBRM1 mutations enriched for the following gene sets: 
glycoproteins; signaling; secreted; and extracellular region (q-values: 2.8E-33; 1.6E-33; 1.5E-26; 9.5E-23, 
respectively). The authors also performed unsupervised clustering of the tumors based on mRNA 
expression, and found a higher PBRM1 mutation rate in a subtype associated with better survival. 
  
Tumor suppression by other SWI/SNF subunits 
 The mechanisms of tumor suppression by other SWI/SNF subunits may also prove illuminating 
for PBRM1 action.  Restoration of SNF5 to a malignant rhabdoid tumor tissue culture model led to re-
expression of p15 and p16 by SNF5 recruitment, along with BRG1, to the promoter regions of these 
genes.  This recruitment was accompanied by the removal of PRC1 (polycomb repressive complex 1) and 
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PRC2 and subsequent loss of the H3K27me3 repressive mark (Kia et al., 2008).  The authors additionally 
saw recruitment of MLL1, a histone methyltransferase, and an increase in the H3K4Me3 active mark.  
This study confirmed earlier work in D. melanogaster which showed that SWI/SNF proteins function as 
trithorax group proteins and oppose the action of polycomb group proteins (Tamkun et al., 1992) (Kal et 
al., 2000).  More recent work has extended this principle to a mouse model where SNF5 is conditionally 
deleted in peripheral T cells, leading to higher levels of EZH2, the methytransferase in the PRC2 
complex, higher H3K27me3 at repressed targets, and ultimately transformation (Wilson et al., 2010).  
Strikingly, double conditional loss of SNF5 and EZH2 completely ablated tumor formation.  The 
antagonism between EZH2 and SWI/SNF extends to other cancer types and SWI/SNF subunits.  For 
example, non-small cell lung cancers with BRG1 mutations display enhanced sensitivity to topoisomerase 
II inhibitors in combination with EZH2 inhibition (Fillmore et al., 2015).  The authors also found that EGFR 
gain-of-function mutant tumors displayed the same sensitivity due to genetic antagonism between EGFR 
and BRG1.  Another report demonstrated a synthetic lethal relationship between EZH2 inhibition and 
ARID1A mutations in ovarian cancer cells (Bitler et al., 2015). 
Previous studies have also demonstrated that one must consider what remains of the SWI/SNF 
complex when investigating mutations in individual subunits.  For example, SNF5 loss is only 
transforming when BRG1 is present, implying that aberrant SWI/SNF activity, but not the total lack of 
activity, is oncogenic (Wang et al., 2009).  A recently identified SWI/SNF complex member, SS18, also 
dramatically alters complex formation when mutated in cancer (Kadoch and Crabtree, 2013).  SS18 is 
part of a chromosomal translocation found in practically all cases of synovial sarcoma (the SS18-SSX 
fusion).  This oncogenic fusion protein competes for binding in the complex with wild-type SS18, and 
displaces SNF5 from the complex.  The cancer-associated complex is then capable of binding to the 
SOX2 locus, resulting in decreased H3K27Me3 levels and increased SOX2 transcription. 
Numerous recent reports have also demonstrated a synthetic lethal relationship between 
homologous SWI/SNF subunits.  For example, two independent studies identified BRM as an essential 
gene in BRG1 mutant cancers (Hoffman et al., 2014) (Wilson et al., 2014).  In the BRG1 mutant setting, 
BRM is upregulated and is incorporated more into residual SWI/SNF complexes.  When BRM is then 
depleted, the cells undergo cell cycle arrest and senescence.  ARID1A and ARID1B, mutually exclusive 
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subunits in the BAF complex, exhibit a similar relationship (Helming et al., 2014b).  Although co-mutations 
of these genes occur, suggesting some cancer-promoting cooperativity, at least one functional allele of 
ARID1B remains in the ARID1A mutant setting.  These studies indicate that some level of SWI/SNF 
activity may be essential for growth in cells, and suggest specific cancer vulnerabilities that could be 
targeted therapeutically.   
As is the case for PBRM1, other SWI/SNF subunits are involved in maintaining genomic stability.  
A 2009 study found BRG1, but not BRM or SNF5, was responsible for maintaining the heterochromatic 
state of pericentromeric regions, and that BRG1 deficiency led to the appearance of micronuclei and 
aberrant mitoses (Bourgo et al., 2009).  BRG1 activity is also required for the decatenation of sister 
chromatids after replication through the action of topoisomerase IIalpha (TOP2A) (Dykhuizen et al., 
2013).  With BRG1 deficiency or the expression of cancer-associated BRG1 mutants, resulting in less 
accessible chromatin, TOP2A has a decreased ability to bind to the genome, resulting in anaphase bridge 
formation and G2/M-phase block, eventually leading to an increased percentage of cells with >4n DNA 
content. 
 
Clear Cell Renal Cell Carcinoma 
It is estimated that ~62,000 new patients in the United States will be diagnosed with kidney 
(renal) cancer in 2015 (Society, 2015).  Nearly all of these cancers will be renal cell carcinoma, which can 
be further classified based on histological appearance.  A large majority of renal cell carcinomas (~75%) 
will be of the clear cell subtype (ccRCC), which is defined by the appearance of “clear” cytoplasm in cells 
typically arranged in nests with interspersed blood vessels (Larkin et al., 2012).  Nearly two-thirds of 
ccRCC cases are diagnosed when the cancer is still local (Society, 2015).  These patients are primarily 
treated with surgical resection or nephrectomy, which is generally curative: the 5-year relative survival is 
92%.  However, in patients with metastatic or recurrent disease, treatment options are limited and 
disease-free survival rates are poor.  ccRCC is largely resistant to traditional chemotherapy and radiation.  
For metastatic cases, approved therapies include cytokine therapy (IFNα and IL-2), anti-mTOR drugs 
(temsirolimus and everolimus), and anti-VEGF therapy, including tyrosine kinase inhibitors that target 
VEGF-receptors in addition to other kinases (bevacizumab, pazopanib, sorafenib, sunitinib, and axitinib) 
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(Institute, 2015).  While these therapies delay disease progression and some extend overall survival rates 
by a few months, very rarely are they curative.   
The development of ccRCC has long been associated with inactivating mutations of the Von-
Hippel Lindau (VHL) gene, which normally negatively regulates the activity of Hypoxia-Inducible Factors 
(HIF-1α and HIF-2α) (Latif et al., 1993) (Iliopoulos et al., 1995) (Iliopoulos et al., 1996).  In normoxic 
conditions, VHL, which is an E3-ubiquitin ligase, targets HIFα subunits for degradation (Maxwell et al., 
1999) (Ohh et al., 2000).  In hypoxic conditions, or in the absence of VHL, HIFα subunits are stabilized, 
and induce a pro-angiogenic transcriptional program.  Through the efforts of large-scale cancer 
sequencing projects, it is now known that VHL activity is lost through a variety of mechanism (e.g., 
mutation with LOH, deletion, promoter hypermethylation) in >90% of ccRCC tumors (Cancer Genome 
Atlas Research, 2013) (Sato et al., 2013).  Inactivation of VHL is thus considered to be a “truncal” event 
seemingly required for the development of ccRCC (Gerlinger et al., 2012) (Gerlinger et al., 2014). 
 Previous studies have demonstrated, however, that VHL loss alone is not enough to induce 
ccRCC (Ma et al., 2003) (Young et al., 2008).  Loss of heterozygosity studies implied the existence of a 
“gatekeeper” gene or genes at chromosomal location 3p21 – the genomic location of PBRM1 (van den 
Berg et al., 1996) (Clifford et al., 1998).  Recent sequencing studies of ccRCC have also implicated 
KDM6A, KDM5C, SETD2, and BAP1, all histone modifying enzymes, as being mutated in ~10-15% of 
ccRCC, stressing the important role of chromatin modification in this lineage of cancer (Dalgliesh et al., 
2010) (Pena-Llopis et al., 2012).  Strikingly, SETD2 and BAP1 are also located at chromosome position 
3p21.  In ccRCC, one arm of 3p is lost in nearly all cases (91%), leaving cells vulnerable to mutation of 
the other allele of these tumor suppressors (VHL is also located nearby at 3p25) (Cancer Genome Atlas 
Research, 2013).  However, while PBRM1 and SETD2 are often mutated concurrently, BAP1 and 
PBRM1 mutations are anticorrelated (Pena-Llopis et al., 2012).  Gene expression profiling of BAP1 
versus PBRM1 mutant ccRCCs suggests that they regulate different gene expression programs.  
Additionally, compared to PBRM1 mutant tumors, BAP1 mutant tumors are of higher grade and worse 
survival (Kapur et al., 2013) (Joseph et al., 2015).  From these studies, the authors concluded the BAP1 
and PBRM1 mutant tumors may be distinct molecular genetic subtypes. 
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Large-scale genetic profiling studies of ccRCC have also detected mutations in other SWI/SNF 
subunits, albeit at much lower rates than PBRM1 mutation (Cancer Genome Atlas Research, 2013) (Sato 
et al., 2013).  ARID1A and ARID1B were hemizygously deleted in 10% and 20% of tumors, respectively, 
in one study (Sato et al., 2013), while both studies detected mutations in SMARCA4 and ARID1A in a low 
percentage of tumors.  These studies also implicated other pathways as being frequently altered in 
ccRCC, including the PI3K-AKT pathway. 
 
The importance of understanding mechanisms of tumor suppression by PBRM1 
 Cancer sequencing studies have revealed that numerous subunits of the SWI/SNF chromatin 
remodeling complex are widely mutated in human malignancies.  PBRM1, a defining subunit of the PBAF 
type of SWI/SNF complex, is mutated in a variety of cancers, including in ~40% of clear cell renal cell 
carcinomas (ccRCC), making it the second most highly mutated gene in ccRCC (behind VHL).  Although 
many recent studies have looked at how other SWI/SNF components function in cancer control, relatively 
little is known about the tumor suppressive mechanisms of PBRM1 in ccRCC.  Additionally, there is a 
large unmet need for more effective therapies for metastatic ccRCC.  In this original research study, we 
will investigate how PBRM1 functions as a tumor suppressor in ccRCC.  In doing so, we hope to gain 
better insight into the molecular mechanisms underlying oncogenic transformation in ccRCC, and 
















BACKGROUND AND SIGNIFICANCE 
 Past studies and cancer sequencing efforts have identified PBRM1 as a tumor suppressor that is 
recurrently mutated in various cancers, including ccRCC, cholangiocarcinoma, gastric adenocarcinoma, 
PDA, and breast cancer.  Many of these studies also explored how PBRM1 functions in cancer control.  
For example, the studies from the Parsons lab first identifying PBRM1 as a tumor suppressor indicated 
that it exerts cell cycle control through induction of p21 (Xia et al., 2008).  Restoration of PBRM1 
expression in the breast cancer line HCC1143 resulted in G1 arrest induced by PBRM1 binding to the 
p21 promoter.  In the 2011 ccRCC exome sequencing study, knockdown of PBRM1 in ccRCC cell lines 
with wild-type PBRM1 led to increased proliferation, growth in soft agar, and migration (Varela et al., 
2011).  Gene set enrichment analysis of microarray data from these knockdown experiments supported 
PBRM1’s role in cell cycle control, and also associated it with chromosomal stability.  Other ccRCC 
genetic profiling efforts have linked PBRM1-mutant tumors to other pathways, including glycoproteins, 
and secreted and signaling pathways (Cancer Genome Atlas Research, 2013) (Pena-Llopis et al., 2012).  
While these studies have provided valuable insight into some PBRM1 tumor suppressor actions, we 
believe that others have yet to be uncovered, particularly for PBRM1 action in ccRCC.   
In this chapter, we manipulate the expression of PBRM1 in ccRCC cell lines to create tools to 
study its function.  We then use various assays to assess how PBRM1 deficiency affects growth.  We 
hypothesize that because numerous studies have identified PBRM1 as a tumor suppressor, PBRM1 
deficiency will increase the growth properties of cells.  We also perform gene expression profiling to 












PBRM1 protein levels can be stably knocked-down with lentiviral shRNA vectors 
As a tool to study PBRM1 function in ccRCC, we created cell lines in which we stably knocked-
down PBRM1 expression levels.  786-O is a VHL-negative ccRCC cell line commonly used in the study of 
this disease (Iliopoulos et al., 1995) (Varela et al., 2011).  It also contains wild-type PBRM1.  We 
transduced 786-O cells with two different lentiviral vectors containing shRNA targeting PBRM1 (termed 
PBRM1 shRNA #1 and #2), or with a lentiviral vector containing an off-target shRNA as a control (control 
or “C” shRNA).  PBRM1 shRNAs #1 and #2 reduced PBRM1 mRNA levels 70% and 85%, respectively 
(Figure 2.1A).  Even greater levels of knockdown were achieved at the protein level: for shRNA #1, 
protein levels were reduced ~90%; and for shRNA #2, protein levels were reduced nearly 100% (Figure 
2.1B).  These levels of knockdown were stable over time. 
We performed the same knockdown procedure in the ACHN renal cell carcinoma cell line.  The 
ACHN cell line has a heterozygous nonsense mutation of PBRM1, but seems to have near-normal levels 
of wild-type PBRM1 by Western blot, and PBRM1 siRNA knockdown causes a significant increase in 
proliferation (Varela et al., 2011).  It has no noted VHL mutations.  Although we only achieved ~50% and 
70% reductions in mRNA levels using PBRM1 shRNAs #1 and #2 in this cell line, protein levels of 
Figure 2.1 – PBRM1 knockdown in 786-O ccRCC cell line. A.) Quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) analysis of PBRM1 mRNA levels 
(relative to GAPDH) in 786-O cells transduced with lentiviruses containing an off-target 
shRNA (C), or PBRM1-targeting shRNA (#1 and #2).  Error bars represent standard 
deviations from n=3. The delta-delta-Ct method was used to analyze the data, with 
786-O control shRNA set to 1. B.) Western blot analysis of PBRM1 protein levels in 
the 786-O lines described in (A).  
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PBRM1 were reduced dramatically with both hairpins (Figure 2.2A and B).  In subsequent experiments, 
we will primarily work with the 786-O lines we created, and will use the ACHN cell lines for confirmatory 













Stable expression of wild-type PBRM1 or cancer-associated mutants in a null setting 
The A-704 cell line is another ccRCC line (VHL mutant) that contains a homozygous truncating 
mutation of PBRM1 (Varela et al., 2011) (see Table 2.1 for a summary of notable mutations in the RCC 
cell lines).  We transduced these cells with either an empty-vector containing retrovirus (hereafter referred 
to as EV) or a retrovirus containing wild-type PBRM1 with a C-terminal V5 tag (referred to as WT) (Figure 
2.3A).  After the initial selection period, PBRM1 expression was stable over time in the A-704 WT cells – 
no PBRM1 expression was detectable in the EV line.  We also introduced cancer-associated mutant 
versions of PBRM1 into these cells.  Examining the spectrum of PBRM1 mutations, the ccRCC exome 
sequencing study identified two in-frame deletions, both in the context of 3p LOH: a six-amino acid 
deletion (p.M1209_E1214delMFYKKE) in the second BAH domain (6AAD), and a single amino acid 
deletion (Ile57) in the first bromodomain (Varela et al., 2011).  Additionally, the authors scored the nine 
missense mutations identified for likelihood of functional impact, and found that three mutations (p.T232P, 
p.A597D and p.H1204P) were likely to have a deleterious effect.  We introduced these mutations into our 
Figure 2.2 – PBRM1 knockdown in ACHN RCC cell line. A.) qRT-PCR analysis of 
PBRM1 mRNA levels (relative to GAPDH) in ACHN cells transduced with lentiviruses 
containing an off-target shRNA (C), or PBRM1-targeting shRNA (#1 and #2).  Error 
bars represent standard deviations from n=3. The delta-delta-Ct method was used to 
analyze the data, with ACHN control shRNA set to 1. B.) Western blot analysis of 
PBRM1 protein levels in the ACHN lines described in (A).  
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PBRM1 expression vector (except for the Ile57 deletion mutation, which we were unable to generate), 
and transduced the A-704 cells to generate stable expression lines (Figure 2.3B).  We were unable to 
detect expression of the A597D mutant, possibly indicating that the mutant protein is unstable and is 
degraded.  Similarly, the 6AAD mutant was expressed at very low levels compared to WT.  On the other 
hand, the T232P and H1204P mutants expressed at comparable levels to the WT protein.  For this 
reason, we decided to use these mutant protein lines in future experiments. 
To check whether our exogenously expressed, V5-tagged proteins (WT, H1204P, and T232P) 
successfully incorporated into PBAF complexes, we performed V5-immunoprecipitation experiments 
using nuclear extracts from each cell line (Figure 2.3C).  The WT and mutant proteins all bound to BRG1 
and SNF5 (core SWI/SNF subunits), and to ARID2 (PBAF-specific), indicating that the exogenously 
expressed proteins were incorporated into PBAF complexes.  This result further implies that exclusion of 
PBRM1 from the PBAF complex is not a tumor-promoting mechanism for these missense mutations. 
PBRM1 deficiency results in faster 2-D growth in reduced serum conditions 
 As PBRM1 is a tumor suppressor, we expected PBRM1 knockdown in the 786-O and ACHN cell 
lines to increase growth rates when the cells were grown on tissue culture plates (2-D growth).  
Alternatively, when WT PBRM1 was expressed in A-704 cells, we expected the cells to grow slower.  
However, at normal culturing conditions using 10% fetal bovine serum (FBS), the growth rates between 
the +PBRM1 and –PBRM1 conditions were not dramatically different (Figure 2.4A-C, left column).  For 




PBRM1 status VHL status HIF1α status 
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Table 2.1 – Summary of notable mutations in the RCC cell lines.  CCLE refers to the Cancer Cell Line 
Encyclopedia, and cBio to the cBioPortal for Cancer Genomics. 
22 
 
although the gap with the control cells was not very large.  shRNA #2 did not increase growth at all, and 
in fact led to slightly slower growth in the 786-O cells.  In the A-704 cells, expression of WT PBRM1 
slowed growth compared to the EV control, but, again, not very dramatically. 
 We hypothesized that stressing the cells by growing them in reduced serum conditions could 
widen the growth gap.  When the 786-O cells were grown in 1% serum, both PBRM1 hairpin lines grew 
significantly faster than control cells (Figure 2.4A, right panel).  The same was true for the ACHN lines 
grown in 6% serum (Figure 2.4B, right panel).  Likewise, when the A-704 cells were grown in 6% serum, 
the growth difference between the EV and WT cells widened dramatically (Figure 2.4C, right panel).  The 
Figure 2.3 – Stable expression of wild-type PBRM1 or cancer-associated mutants in 
A-704. A.) The PBRM1 null cell line A-704 was transduced with either empty-vector 
containing retrovirus (EV), or a retrovirus containing wild-type PBRM1 with a C-terminal V5 
tag (WT).  After selection, expression of PBRM1 was checked via Western blot analysis 
using an antibody against PBRM1.  B.) A-704 cells were also transduced with various 
retroviruses containing cancer-associated mutant PBRM1.  Expression was checked via 
Western blot analysis. C.) V5-immunoprecipitation experiments were performed using 
nuclear extracts from the indicated A-704 cell lines created in (A) and (B).  Western blot 
analysis was performed to check for binding to SNF5, ARID2, and BRG1. 
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growth differences that emerge at reduced serum conditions largely seem to be the result of the cells 
containing PBRM1 losing their ability to proliferate. 
 We also tested the growth effects of expressing the H1204P and T232P mutants in A-704 cells 
and saw similar results.  At full serum, the growth differences between the WT and cancer-mutant lines 
Figure 2.4 – 2-D Growth Curves of RCC cell lines at normal and reduced serum 
conditions. A.) 2-D growth curves of the indicated 786-O cell lines grown on 48-well 
tissue culture plates at normal (10%) and reduced (1%) FBS. n=6 per timepoint for each 
line. B.) Growth curves of the ACHN lines at normal (10%) and reduced (6%) FBS. n=4-6 
per timepoint for each line. C.) Growth curves of the A-704 lines at normal (10%) and 
reduced (6%) FBS. n=3 per timepoint for each line. Two-way ANOVAs using Tukey’s 
multiple comparisons test was performed on each set of growth curves. * P<0.05; ** 
P<0.01; *** P <0.001; **** P<0.0001. 
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were minimal – at later timepoints, the T232P mutant line grew slightly slower than the WT line, and all 
lines grew slower than the EV control line (Figure 2.5A).  At reduced serum conditions (6%), a growth gap 
emerged, in which all lines grew significantly faster than the WT line (Figure 2.5B).  However, compared 
to the EV control line, the cancer-mutant lines still grew significantly slower, suggesting that the cancer 
mutants may be behaving in a hypomorphic manner. 
PBRM1 knockdown increases the 3-D growth capacity of cells 
 When the RCC cell lines were placed under more stressful conditions by growing them at 
reduced serum, a significant growth advantage conveyed by PBRM1 deficiency emerged.  We reasoned 
that a similar situation might occur using 3-D growth assays, which more stringently test the transformed 
nature of cells.  First, we compared the ability of our cell lines to form colonies in soft agar, a measure of 
anchorage independent growth and tumorigenic potential.  In both 786-O and ACHN cells, PBRM1 
knockdown with either hairpin significantly increased colony forming capacity (Figure 2.6).  The A-704 cell 
lines were unable to form colonies in soft agar.     
As a further test of the 3-D growth capacity of PBRM1 knockdown cells, we performed tumor 
xenograft experiments with 786-O control shRNA and PBRM1 shRNA #2 cells.  One million cells of each 
line were subcutaneously injected into the ventral surface of nude mice.  After an initial latency period, the 
Figure 2.5 – 2-D Growth Curves of all A-704 lines at normal and reduced serum 
conditions. 2-D growth curves as in Figure 2.4, except growth data was collected using an 
Incucyte Zoom machine as a % confluence of a well on a tissue culture plate. A.) 2-D growth 
curves of the indicated A-704 cell lines grown on 48-well tissue culture plates at normal (10%) 
and B.) reduced (6%) FBS. n=3 per timepoint for each line. Two-way ANOVAs using Tukey’s 
multiple comparisons test was performed on each set of growth curves, and significant 
differences with the WT line are shown. * P<0.05; ** P<0.01; *** P <0.001; **** P<0.0001. 
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PBRM1 knockdown cells grew significantly faster than the control cells (Figure 2.7A), and had formed 
significantly larger tumors by the time the mice were euthanized (Figure 2.7B,D).  Protein extracted from 
the tumors and analyzed by Western blot analysis confirmed PBRM1 knockdown persisted in the PBRM1 
shRNA line (Figure 2.7C). 
 
Murine embryonic fibroblasts with conditional loss of Pbrm1 grow slower than matched controls 
 Murine embryonic fibroblasts (MEFs) are typically used to study the effects of a particular genetic 
event, such as gene loss, in a “clean” genetic background compared to tumor cell lines, which often 
contain a plethora of additional mutations.  To this end, we isolated MEFs from conditional Pbrm1 mice 
we had generated in which LoxP sites were engineered to flank exon 2 of the Pbrm1 allele, such that Cre-
mediated recombination would result in a frame-shifting mutation.  Using three sets of MEFs from 
different embryos, we infected either with adenovirus expressing Cre-recombinase (NULL cells) or GFP 
as a control (WT cells).  Western blots analysis indicated effective recombination and loss of Pbrm1 
expression in the NULL cells (Figure 2.8A).  Growth curve analysis, however, revealed that the Pbrm1 
NULL MEFs grew significantly slower than the WT controls (Figure 2.8B).  This was not totally surprising, 
as tumor suppressor loss-induced senescence has been observed for other tumor suppressors in MEFs, 
including for VHL (Young et al., 2008). 
Figure 2.6 – PBRM1 knockdown in 786-O and ACHN cells increases 
colony formation in soft agar.  Single cell suspensions of 786-O (A) and 
ACHN (B) were plated with soft agar and colony formation was measured 
after 23 days.  Error bars represent standard errors of the mean (SEM), 





RNA-seq and microarray analysis reveal cancer-related pathways perturbed with PBRM1 
deficiency 
RNA-seq analysis of 786-O and A-704 cell lines 
 Having created various cell culture systems of PBRM1 alteration, we next asked what genes and 
transcriptional programs were influenced by PBRM1.  To answer this question using the 786-O and A-704 
cell lines, we employed RNA-seq, a technique which uses next-generation sequencing to quantify mRNA 
transcript levels with wide coverage of the transcriptome and high dynamic range.  Additionally, because 
we saw larger growth differences emerge at reduced serum conditions, we decided to quantify mRNA 
levels in cells growing at normal and reduced serum conditions.  mRNA from the 786-O control shRNA 
Figure 2.7 – PBRM1 knockdown in 786-O cells significantly increases tumor 
xenograft growth.  One million cells of 786-O control shRNA or PBRM1 shRNA #2 cells 
were subcutaneously injected into the ventral surface of athymic nude mice (n=4).  A.) 
Tumors were palpable after 10 days, and tumor growth was then tracked until tumors 
exceeded 1cm3, at which time the mice were euthanized. B.) Excised tumor xenografts of 
indicated lines after mice euthanasia on day 34 post-injection – excised tumor weights are 
shown in (D).  C.) Western blot analysis of protein extracted from tumor xenografts. For the 
growth curve in (A), two-way ANOVA using Tukey’s multiple comparisons test was 
performed.  For the tumor weight comparison in (D), an unpaired t-test was performed.  * 
P<0.05; ** P<0.01; *** P <0.001; **** P<0.0001.   
27 
 
and PBRM1 shRNA #1 and #2 lines and the A-704 EV and WT lines was isolated, RNA-seq libraries 
were prepared, and 100 base-pair (bp) single-end sequencing was performed using an Illumina HiSeq 




# of Reads 
(x106) 
786-O control shRNA 10 45.0 
786-O PBRM1 shRNA #1 10 27.5 
786-O PBRM1 shRNA #2 10 36.4 
786-O control shRNA 1 41.1 
786-O PBRM1 shRNA #1 1 41.5 
786-O PBRM1 shRNA #2 1 36.0 
A-704 EV 10 28.5 
A-704 WT 10 39.1 
A-704 EV 6 31.6 
A-704 WT 6 46.4 
Next, we processed the RNA-seq raw data using the Tuxedo suite of tools and aligned our reads 
using Cufflinks.  Cuffdiff was used for expression comparisons between samples (e.g., A-704 EV vs. WT 
at 6% serum), generating RPKM, fold-change, and p-values.  Before proceeding to the next stage of 
analysis, however, we wanted to filter out genes with very low RPKM values regardless of PBRM1 status, 
Figure 2.8 – MEFs with conditional loss of Pbrm1 grow slower than matched control cells.  
Three sets of Pbrm1 fl/fl MEFs were infected with a GFP or Cre-expressing adenovirus to 
generate Pbrm1 WT and NULL MEFs, respectively. A.) Western blot analysis showing loss of 
Pbrm1 expression in the NULL MEFs. B.) Growth curve analysis of MEF sets from part (A).   
n=3/line at each timepoint, error bars represent SEM. Two-way ANOVA using Tukey’s multiple 
comparisons test was performed on the growth curves. * P<0.05; ** P<0.01; *** P <0.001; **** 
P<0.0001. 




reasoning that these genes were not biologically relevant in this context and could significantly alter 
downstream analysis, such as gene set enrichment analysis (GSEA).  To find the proper RPKM cutoff, we 
generated histograms of cumulative RPKM (summing the +PBRM1 and –PBRM1 conditions, and using 
an average RPKM value for the PBRM1 shRNAs) for each cell line at each serum concentration (Figure 
2.9).  In all settings, ~80% of the mapped genes had a cumulative RPKM less than or equal to 10.  We 
excluded these low abundance transcripts and focused our analysis on the more highly expressed genes, 
now termed the “expressed” genes (9,744 genes for 786-O normal serum; 9,846 genes for 786-O 
reduced serum; 9,664 genes for A-704 normal serum; 9,798 genes for A-704 low serum).  After filtering, 
histograms of the fold-change values (-PBRM1 condition/+PBRM1 condition) were bell-curve shaped 
(Figure 2.10).  
 To more accurately identify genes and pathways altered by PBRM1, and account for cell line-
specific effects, we wanted to limit our analysis to genes that were expressed in both 786-O and A-704 
cells at a given serum concentration, and whose expression changed in the same direction with PBRM1 
deficiency (i.e., same directionality of fold-change with both PBRM1 shRNAs in 786-O and A-704 EV 
compared to A-704 WT).  After filtering on these criteria, we were left with the following gene counts for 
further analysis:  
 
Gene # (direction change with PBRM1 
deficiency) 
Serum Condition UP DOWN TOTAL 
Normal 2,777 1,542 4,319 
Reduced 1,519 2,017 3,536 
At normal serum, more genes had increased expression than decreased with PBRM1 deficiency, 
indicating that PBRM1 was playing more of a repressive role under these conditions.  However, at 
reduced serum, the reverse was true, indicating that PBRM1 was playing more of a transcriptional 
activator role under stressful conditions. 
 To quantify genes whose expression was most impacted by PBRM1 across cell lines, we then 
performed a Fisher’s combined probability test at each serum condition.  This method allows one to pool 
the p-values from independent experiments and perform a meta-analysis, generating a “meta-p-value” for 




each gene.  We used the p-values generated from Cuffdiff comparing gene expression in the following 
sample pairs: 786-O PBRM1 shRNA #1/control shRNA; 786-O PBRM1 shRNA #2/control shRNA; A-704 
EV/WT.  We will also analyze the RNA-seq data without combining later on. 
 
Top-changed genes and pathways with PBRM1 alteration 
 With a single meta-p-value now associated with each gene, we next looked at the top genes with 
expression changes.  Figure 2.11 shows heatmaps of the log2(fold-change) for genes with meta-p-
values<0.01 at each serum condition.  Numerous genes are among the top-changed genes at both serum 
conditions: AIF1L, COL6A1, CLDN2, ID1, ALDH1A1, GPR56, AMACR, CLU, IL8, SERPINE1, 
SNORD118, MXD1, UAP1, CTSS, and IFI27 appear in both heatmaps.  We were particularly interested in 
genes whose alteration would confer a growth advantage under stressful conditions, such as reduced 
serum or a 3-D growth environment.  With this in mind, we took special note of ALDH1A1 due to its 
association with cancer-initiating cells (Pearce et al., 2005) (Ginestier et al., 2007) (Chen et al., 2009) 
(van den Hoogen et al., 2010) (Su et al., 2010).  Other notable genes that only appear on the normal 
serum heatmap include IGFBP3 (a HIF target gene), HIF1A itself, CA2 (carbonic anhydrase II, a known 
connection to ccRCC), EGFL7 (modulates vasculogenesis and Notch signaling), JAG1 (jagged1, a Notch 
receptor ligand), and PMAIP1 (also known as NOXA, a pro-apoptotic factor). 
 To identify pathways and transcriptional programs altered by PBRM1, we then performed gene 
set enrichment analysis (GSEA) using the meta-p-values associated with each gene and the pre-ranked 
gene list analysis option.  Numerous pathways were highly enriched at both serum conditions – the top 15 
enriched gene sets for genes that are upregulated or downregulated with PBRM1 deficiency are shown in 
Figure 2.12.  At normal serum, upregulated genes were enriched for numerous gene sets related to 
translational regulation (KEGG RIBOSOME, REACTOME PEPTIDE CHAIN ELONGATION, REACTOME 
3 UTR MEDIATED TRANSLATIONAL, and REACTOME SRP DEPENDENT COTRANSLATIONAL 
PROTEIN TARGETING TO MEMBRANE). Gene sets related to the classical subtype of glioblastoma 
multiforme, defined by EGFR abnormalities, and retinoic acid signaling were also enriched (VERHAAK 
GLIOBLASTOMA CLASSICAL and MARTENS TRETINOIN RESPONSE UP, respectively).  At reduced 





















































































































































































































































































































































































































































































































































































































































































Figure 2.11 – Heatmaps of the top changed genes with PBRM1 alteration at 
each serum condition.  Heatmaps of the log2(fold-change) of the genes with meta-
p-value<0.01 at each serum condition.  The control conditions (786-O control 























































































































































































































































































































































































































































































































































EGFR (KOBAYAHSI EGFR SIGNALING 24HR UP and ZWANG TRANSIENTLY UP BY 1ST EGF PULSE 
ONLY) and Wilm’s tumor (LI WILMS TUMOR VS FETAL KIDNEY 1 UP).  In the EGFR-related genes 
sets, some of the top upregulated genes include VAV3, CDK6, PDK2, and FGFR4.  Among 
downregulated genes, many enriched gene sets related to interferon signaling (HECKER IFNB1 
TARGETS, SAMA RESPONSE TO IFNG UP, MOSERLE IFNA RESPONSE, BROWNE INTERFERON 
RESPONSIVE GENES).  EZH2-regulated genes also enriched as being downregulated (NUYTTEN EZH2 
TARGETS UP). 
As an alternative method to identify enriched pathways, we also performed gene ontology 
analysis using the gene ontology biological processes (GOBP) database.  We checked for enriched 
processes among genes with meta-p-values<0.05 at each serum condition (Figure 2.13).  At normal 
serum, only six processes were significantly enriched and represented broad categories such as “singe 
organism cellular process” and “small molecule metabolic process.”  At reduced serum, however, 
numerous processes were significantly enriched – the top 20 are shown in Figure 2.13B.  Many of these 
processes related to interferon signaling, defense response, and cytokine signaling, similar to the GSEA 
output.  A cell surface receptor signaling pathway was also enriched. 
 
Microarray analysis of Pbrm1 conditional MEFs 
 To see what genes and pathways were altered in the Pbrm1 NULL MEFs, we used gene 
expression microarrays to perform expression analysis on the three matched sets of MEFs described in 
Figure 2.8.  Aldh1a1 and Igfbp3 were among the top 50 most-altered genes in the MEFs (Figure 2.14A); 
these genes were also found among the top-changed genes in the ccRCC RNA-seq analysis.  GSEA of 
the microarray data did not reveal any enriched pathways with low false-discovery rates (FDR q-
value<0.25) (Figure 2.14B).  However, among the top-enriched pathways in the NULL MEFs, we saw 
retinoic acid-related pathways (DELACROIX RAR TARGETS UP and DELACROIX RAR TARGETS 
DOWN), and among the enriched pathways in the WT MEFs, we saw pathways related to epigenetic 
regulation of gene expression (WANG LSD1 TARGETS UP and KAMMINGA EZH2 TARGETS).  We also 
performed gene ontology analysis, and saw modest enrichment of 5 pathways, including “immune system 






























































































































































































































































































































Figure 2.14 – Significantly altered genes and pathways in Pbrm1 NULL MEFs.  Microarray gene 
expression analysis was performed on three sets of matched Pbrm1 conditional MEFs.  A.) Heatmap of 
the top 50 altered genes in the MEFs.  B.) GSEA of the MEF microarray data.  The top 15 pathways 
enriched in the NULL MEFs are shown in the top panel, and the 14 pathways with P<0.05 enriched in the 
WT MEFs are shown in the bottom panel. C.) Gene ontology analysis of MEF microarray data (P<0.05). 
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Overlap of genes with significant expression changes in 786-O, A-704, and MEFs 
 As an alternative expression analysis method to those prevented above, we identified genes 
whose expression changed significantly in each individual cell line and then looked for any overlaps 
between these genes.  For the 786-O and A-704 cell lines at normal serum (similar condition to the 
MEFs), we used a log2(fold-change) cut-off of 0.4 to call a gene as significantly altered, as shown by the 
dotted lines in Figure 2.10.  For the MEFs, we used a fold-change cut-off of 1.1 (due to the lower dynamic 
range of microarray analysis).  For the 786-O, A-704, and MEFs, 2,196, 1,394, and 433 genes met these 
thresholds, respectively.  Among these genes, there was significant overlap between the 786-O and A-
704 lines (355 genes), and less between these lines and the MEFs (23 and 15 genes), as might be 
expected when comparing human cancer cell lines to non-transformed, primary mouse cells (Figure 
2.15).  Still, ten genes were found to be significantly altered in all settings: IGFBP3, ALDH1A1, and 
EFNA3 were upregulated in all 3 cell lines; WBP5, ESCO2, and PBRM1 were downregulated; and 
NIPAL2, DNAJB14, IL6, and CD47 changed in different directions. 
 
Analysis of primary tumor datasets reveals that ALDH1A1 is overexpressed in PBRM1 mutant tumors 
 We next asked whether any expression changes could be seen in primary ccRCC tumors for the 
six genes (IGFBP3, ALDH1A1, EFNA3, WBP5, ESCO2, and PBRM1) that were consistently upregulated 
Figure 2.15 - Overlap of genes with significant expression changes in 786-O, A-704, and MEFs. 
For 786-O, A-704, and MEFs, genes whose expression changed significantly with PBRM1 deficiency 
were identified using the following cut-offs: log2(fold-change) > 0.4  for 786-O and A-704; and fold-
change > 1.1 for the MEFs.  Gene overlap analysis was then performed.  The ten genes changed in 
all three lines are called-out and their fold-changes are listed. 
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or downregulated with PBRM1 deficiency in our cell culture systems.  To answer this question, we used 
two publicly available ccRCC primary tumor expression datasets: one from the TCGA available on the 
cBioPortal for Cancer Genomics; and the other from the 2012 study from Peña-Llopis et al that profiled 
BAP1 and PBRM1 mutant tumors/tumorgrafts (Pena-Llopis et al., 2012).  We divided the tumors into 
those with PBRM1 mutations (Mut) and those without (WT).  In the TCGA dataset, 122 out of 417 
sequenced tumors had PBRM1 mutations; in the Peña-Llopis et al dataset, 21 out of 53 
tumors/tumorgrafts had PBRM1 mutations.  In the TCGA dataset, 5/6 of the identified genes were 
significantly altered in the PBRM1 mutant setting (Figure 2.16A).  The changes in two of the genes 
(EFNA3 and ESCO2) barely met significance (P=0.045 and P=0.047, respectively).  ALDH1A1, WBP5, 
and PBRM1, however, all had dramatic shifts in expression.  The shift in PBRM1 expression suggests 
that many of the mutations produced unstable transcripts that may undergo nonsense mediated decay.   
 In the Peña-Llopis et al dataset, only ALDH1A1 was among the significant genes that 
distinguished PBRM1 mutant vs. non-mutant tumors.  In fact, in this dataset, ALDH1A1 was even more 
dramatically upregulated in the PBRM1 mutant tumors (Figure 2.16B).  To see if this upregulation was 
specific to PBRM1 mutant tumors, we divided the TCGA tumors by SETD2 and BAP1 mutation status and 
saw no correlation with ALDH1A1 expression levels (Figure 2.16C).  Based on this analysis, we 




 Like many other SWI/SNF subunits, PBRM1 is recurrently mutated in numerous cancers, 
although it has a particularly high mutation rate in ccRCC (Varela et al., 2011) (Cancer Genome Atlas 
Research, 2013).  While previous studies have investigated PBRM1’s tumor suppressor functions, and 
implicated PBRM1 in cell cycle control and chromosomal stability (Xia et al., 2008) (Varela et al., 2011), 
we believe key genes and pathways under PBRM1 control have yet to be identified.  Therefore, in this 
chapter, we set out to create cell culture tools to study PBRM1 function in ccRCC.  After characterizing 





 In the RCC cell lines 786-O and ACHN, stable knockdown of PBRM1 dramatically increased 2-D 
growth in tissue culture plates, but only at reduced serum conditions (Figure 2.4A,B).  In the A-704 
ccRCC line, which possesses a homozygous truncating mutation of PBRM1, stable expression of wild-
type PBRM1 substantially reduced growth, but again only at reduced serum (Figure 2.4C).  These 
findings suggest that the growth advantages conveyed by PBRM1 loss may only emerge under stressful 
conditions, such as those encountered by a nascent tumor.  This conclusion is further supported by the 
robust 3-D growth advantage of PBRM1 knockdown cells, as seen by colony formation in soft agar 
Figure 2.16 – ALDH1A1 is upregulated in PBRM1 mutant tumors. A.) Provisional TCGA data for ccRCC 
was taken from the cBioPortal for Cancer Genomics in November 2015 – 417 tumor samples had 
sequencing and expression data available.  We divided the tumors into those with PBRM1 mutations (Mut) 
and those without (WT) – 122/417 tumors were mutated.  mRNA z-score levels are shown for the 6 listed 
genes. B.) We used ccRCC expression data from Peña-Llopis et al to see if any of the genes from (A) was 
among the significant genes that distinguished PBRM1 mutant vs. non-mutant tumors – only ALDH1A1 was 
differentially expressed (21/53 tumors had PBRM1 mutations). Relative mRNA levels are shown. C.) The 
TCGA data from (A) was divided based on SETD2 and BAP1 mutation status – 52/417 tumors had SETD2 
mutations, and 36/417 had BAP1 mutations.  ALDH1A1 mRNA z-score levels are shown.  All plots 




(Figure 2.6).  Additionally, tumor xenograft studies using the 786-O line revealed that PBRM1 knockdown 
cells grow significantly faster and form significantly larger tumors than control cells in vivo (Figure 2.7).  
Together, these data suggest that PBRM1 deficiency helps a cell adjust to stressful environments, 
whether it be reduced serum, anchorage independence, or the subcutaneous compartment of a nude 
mouse, and continue to grow.  Investigating genes and pathways influenced by PBRM1 that may 
contribute to this growth advantage will be the subject of the next chapter. 
In the A-704 line, stable expression of cancer-associated mutant forms of PBRM1 (H1204P and 
T232P) resulted in faster growth than expressing WT PBRM1, but still slowed growth compared to the EV 
control line (Figure 2.5).  Although the large majority of PBRM1 mutations in primary tumors are 
nonsense, truncating mutations, which are expected to be true loss of function mutations, missense 
mutations in the context of LOH do occur.  This growth finding suggests that at least some of these 
mutations may function as hypomorphs, in which some functions of PBRM1 may be lost while others 
remain intact.  Further exploring these mutants and their effects compared to WT PBRM1 may aid in the 
discovery of structure:function relationships, and will be done in experiments in later chapters. 
Additionally, some of the PBRM1 mutants could not be stably expressed, such as the A597D 
mutant, or could only be expressed at very low levels, such as the 6AAD mutant.  While this could be due 
to instability of the produced protein, it could also result from failure to incorporate into the PBAF complex, 
eventually leading to protein degradation.  We also did not explore if other types of PBRM1 mutations, 
such as some of the truncating mutations, lead to stable expression of PBRM1 protein fragments, and if 
so, how these proteins affect PBAF assembly.  As truncating mutations are much more prevalent than 
missense mutations, this would be an interesting avenue for further exploration.  
Due to the widening growth gap at reduced serum conditions, we decided to perform RNA-seq 
expression profiling on the 786-O and A-704 lines grown at both normal and reduced serum conditions.  
We believed that doing so would give us a better chance of identifying key growth and cancer-related 
pathways under PBRM1 regulation.  We also performed Fisher’s combined probability test to conduct a 
meta-analysis in which we could combine the RNA-seq results from the two separate cell lines, ones in 
which we approached PBRM1 alteration from opposing directions – knocking down in the WT setting 
(786-O), or restoring in the mutant setting (A-704).  We hoped that this approach would allow us to 
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account for cell-line specific effects and biases related to using shRNA vectors or over-expressing a gene 
of interest.  
After processing the RNA-seq data in this fashion, we performed GSEA and gene ontology 
analysis to identify enriched pathways and biological processes (Figure 2.12 and 2.13).  Although 
numerous pathways and processes were altered, a few themes emerged from this analysis.  First, at 
normal serum, among upregulated genes with PBRM1 deficiency, numerous pathways enriched related 
to translational regulation.  Although we don’t follow up on this finding in this dissertation, future studies 
could investigate PBRM1’s role in translational control, as this would be expected to have wide-ranging 
effects on a cell.  Second, at both normal and reduced serum, among upregulated genes, pathways 
enriched related to the EGFR pathway.  Given the EGFR pathway’s well-known roles in growth and 
cancer development, and the genetic antagonism between the pbap complex and the EGFR pathway 
previously found in flies, we will investigate this pathway further in the next chapter (Rendina et al., 2010) 
(Curtis et al., 2011).  Lastly, at reduced serum conditions, among downregulated genes, numerous 
enriched GSEA pathways and GO processes related to interferon signaling.  One of the top 
downregulated genes at both serum conditions was IFI27, or Interferon, Alpha-Inducible Protein 27, a 
supposed pro-apoptotic interferon-response gene (Figure 2.11).  We will also investigate this pathway in 
relation to PBRM1 in Chapter 3. 
We also conducted expression profiling in our conditional Pbrm1 MEFs, a non-transformed, 
primary mouse line (Figure 2.14).  We hypothesized that any genes whose expression changed across all 
three of these systems (786-O, A-704, and MEFs) might be true PBRM1-regulated genes.  Indeed, we 
saw ten genes regulated across all systems, including six that changed in the same direction with PBRM1 
deficiency (Figure 2.15).  PBRM1’s presence on this list as a consistently downregulated gene served as 
a nice control for this analysis method.  Finally, we used two publicly available ccRCC datasets to see if 
any of these genes were differentially expressed in primary tumors with PBRM1 mutations.  We found 
that ALDH1A1 was significantly upregulated in PBRM1 mutant tumors in both datasets (Figure 2.16).  In 












CHAPTER 3: PBRM1 suppresses tumorigenic potential through regulation of 




BACKGROUND AND SIGNIFICANCE 
 In Chapter 2, we created cell culture tools to study PBRM1 function in ccRCC, and subsequently 
conducted gene expression profiling using these tools.  We analyzed the expression data to identify the 
top-changed genes and enriched pathways and processes.  These efforts yielded some interesting 
results.  Across our cell line systems, a few genes were consistently upregulated or downregulated with 
PBRM1 deficiency (IGFBP3, ALDH1A1, EFNA3, WBP5, ESCO2, and PBRM1).  Previously, PBRM1 had 
not been connected to the regulation of any of these genes.  We then asked whether any of these genes 
were differentially expressed in primary tumors, and found that ALDH1A1 expression was increased in 
PBRM1 mutant tumors. 
ALDH1A1 is also known as aldehyde dehydrogenase 1 or retinaldehyde dehydrogenase 1.  It is 
one of a class of oxidizing enzymes that convert aldehydes to carboxylic acids (Xu et al., 2015).  It is part 
of the retinoic acid metabolic pathway and irreversibly converts retinaldehyde to retinoic acid (ALDH1A2 
and ALDH1A3 can also perform this step).  Aldehyde dehydrogenases (ALDHs) also perform other 
functions in a cell, such as protecting against a variety of environmental stressors by serving as aldehyde 
scavengers (Singh et al., 2013).  For example, ALDHs are thought to protect against oxidative stress and 
UV damage and to help catalyze the breakdown of lipid peroxides. 
ALDH1A1 has known roles in hematopoetic stem cell development (Ghiaur et al., 2013) (Chanda 
et al., 2013), white vs. brown fat programming (Kiefer et al., 2012b), and insulin signaling (Kiefer et al., 
2012a).  It has also been identified as a marker of tumor-initiating cells or cancer-stem cells in a variety of 
cancer types (Pearce et al., 2005) (Ginestier et al., 2007) (Chen et al., 2009) (van den Hoogen et al., 
2010) (Su et al., 2010).  The cancer stem cell theory holds that a small population of cells within the 
cancer actually drive the cancer, and that these cells possess unique properties, related to such things as 
self-renewal capacity, multipotency, resistance to therapeutics, and ability to seed new tumors (Nguyen et 
al., 2012). This association between ALDH1A1 and cancer stem cells seems paradoxical at first glance, 
as retinoic acid signaling is traditionally associated with a more differentiated state.  Various mechanisms, 
however, have been proposed to explain ALDH1A1’s association with increased tumorigenicity.  For 
example, increased retinoic acid formed from higher ALDH1A1 activity could participate in non-classical 
retinoic acid signaling, whereby PPARβ/δ activation has anti-apoptotic, pro-growth effects (Schug et al., 
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2007).  ALDH1A1’s cancer-promoting effects could also be mediated through non-retinoic acid related 
mechanisms, such as protection from reactive oxygen species or limiting the toxicity of drugs (Singh et 
al., 2013) (Huang et al., 2013) (Corominas-Faja et al., 2013) (Raha et al., 2014).  In this chapter, we will 
explore PBRM1 regulation of ALDH1A1 and how it impacts tumorigenic potential. 
We also identified the EGFR and IFN pathways as being potentially affected by PBRM1 status.  
Both these pathways not only have relevance to cancer, but have been studied before in relation to 
PBRM1-containing complexes (Rendina et al., 2010) (Curtis et al., 2011) (Yan et al., 2005).  The EGFR 
pathway is a widely studied growth pathway that is frequently altered in cancer (Chong and Janne, 2013).  
Its relevance to cancer is evident by the numerous EGFR inhibitors and blocking antibodies that are 
clinically approved for the treatment of various cancer types.  Although EGFR is not amplified in ccRCC, it 
is frequently overexpressed, and the downstream PI3K pathway is recurrently activated through low 
mutation rates in various other components (Cancer Genome Atlas Research, 2013) (Sato et al., 2013).  
EGFR inhibition in metastatic ccRCC, however, has largely yielded disappointing clinical results, with little 
or no benefit over cytokine therapy (e.g., IFNα) (Drucker et al., 2003) (Ravaud et al., 2008).  IFNα is the 
standard of care therapy for metastatic ccRCC that EGFR inhibitors and other potential new therapies are 
typically compared against.  However, it has limited efficacy and only extends overall survival by a couple 
months (Institute, 2015).  Exploring PBRM1’s role in modulating these pathways may yield clinically 
relevant insights into mechanisms of treatment resistance, at least among this genetic subtype of ccRCC. 
 
RESULTS 
PBRM1 status affects ALDH1A1 mRNA, protein, and activity levels 
 Having established a connection between PBRM1 and ALDH1A1 via RNA-seq in our cell culture 
systems and primary tumors, we first confirmed via qRT-PCR that ALDH1A1 mRNA levels were changing 
(Figure 3.1A).  As expected, PBRM1 knockdown in 786-O increased ALDH1A1 mRNA levels, while 
expression of WT PBRM1 in A-704 decreased ALDH1A1 mRNA levels.  Additionally, the Pbrm1 NULL 
MEFs had significantly higher Aldh1a1 mRNA levels.  We next asked whether these mRNA changes 
extended to protein levels and enzyme activity in our ccRCC cell lines.  In 786-O, both PBRM1 shRNA 
lines expressed significantly higher protein levels of ALDH1A1 compared to the control line (Figure 3.1B).  
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As an additional check, we also probed ALDH1A1 protein levels in the ACHN lines we created, and saw 
similar ALDH1A1 changes (Figure 3.1D).  Alternatively, in A-704, expression of WT PBRM1, but not 
cancer-associated mutant PBRM1, lowered ALDH1A1 protein levels.   
 ALDH1-class enzyme activity can be measured using the ALDEFLUOR assay, a flow-cytometry 
based method that measures the conversion of a fluorescently-tagged aldehyde (bodipy-
aminoacetaldehyde) to an acid (bodipy-aminoacetate) (Corti et al., 2006).  While the aldehyde can freely 
diffuse into and out of the cell, the acid becomes trapped with the cell, leading to higher levels of 
fluorescence.  The ALDH1-class chemical inhibitor 4-Diethylaminobenzaldehyde (DEAB) is used to set a 
negative baseline.  We used this assay to measure ALDH1-class activity in the 786-O and A-704 lines.  
The results mirrored those seen for ALDH1A1 protein levels: PBRM1 knockdown in 786-O increased the 
ALDEFLUOR-positive population of cells by around 50%; while WT PBRM1 expression in A-704 
Figure 3.1 – PBRM1 status affects ALDH1A1 mRNA, protein, and activity levels.  A.) qRT-PCR analysis 
of ALDH1A1 mRNA levels (relative to GAPDH) in the indicated cell lines.  For 786-O and A-704, error bars 
represent standard deviations for n=3.  For MEFs, errors bars represent SEM for n=3. The delta-delta-Ct 
method was used to analyze the data, with 786-O control shRNA, A-704 EV, and WT MEF lines set to 1.  
Unpaired t-tests were performed.  B.) and D.) Western blot analysis of ALDH1A1 protein levels in the 
indicated cell lines.  C.) Percentage of cells that were ALDEFLUOR (+) using the ALDEFLUOR assay, in 
which the chemical inhibitor DEAB was used to set a negative baseline of fluorescence for each cell line.  
n=3 for each line, error bars represent SEM, and unpaired t-tests were performed.   
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decreased the ALDEFLUOR-positive population by ~33%, while the cancer mutants had no impact 
(Figure 3.1C). 
 
PBRM1 knockdown in 786-O increases tumorsphere-forming capacity 
 As ALDH1A1 has been linked to tumor-initiating cells, we next sought to establish whether 
PBRM1 deficiency increased the tumorsphere-forming capacity of cells.  In this assay, the cells are plated 
as single cells at low density on ultra-low attachment plates using serum-free tumorsphere media 
supplemented with growth factors.  The ability of the cells to propagate and form free-floating masses of 
condensed cells (tumorspheres) can then be evaluated.  This method was initially used for the isolation 
and characterization of neural stem cells (neurospheres) (Reynolds and Weiss, 1992), and was later 
adapted for the study of mammary stem cells and breast cancer stem cells (mammospheres) (Dontu et 
al., 2003) (Ponti et al., 2005) (Farnie et al., 2007).  It has subsequently been used for the in vitro study of 
cancer stem or stem-like cells of various lineages, and, like other anchorage-independent growth-assays, 
is thought to represent a good surrogate measure of in vivo tumorigenicity (Freedman and Shin, 1974) 
(Yen et al., 2012) (Zhang et al., 2012) (Qiu et al., 2012) (Kim and Alexander, 2014). 
 PBRM1 knockdown significantly increased the ability of 786-O cells to form free-floating 
tumorspheres (Figure 3.2A, left panel).  When we tried to passage the control and PBRM1 shRNA #2 
tumorspheres (by dissociating the cells and replating at the original density), the PBRM1 shRNA cells 
maintained a substantially higher sphere-forming capacity (Figure 3.2A, right panel), indicating a higher 
self-renewal rate (Shaw et al., 2012).  As part of the passaging process, the number of cells per well after 
dissociation were counted for the control and PBRM1 shRNA #2 tumorspheres.  There were significantly 
more PBRM1 shRNA cells present, indicating that increased tumorsphere formation was not just due to 
increased association of individual cells (Figure 3.2B).  Representative tumorsphere pictures are shown in 
Figure 3.2C.  At the second passage, hardly any tumorspheres formed for the control cells – the picture 
shows a few individual cells clumped together, which do not meet the criteria for a tumorsphere. 
 
Expression of the T232P PBRM1 cancer mutant increases tumorsphere formation in A-704 cells 
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 We also tested the tumorsphere-formation capacity of the A-704 cells.  Overall, the A-704 cells, 
including the control EV line, formed fewer tumorspheres than the 786-O cells (Figure 3.3).  Expression of 
both WT and H1204P PBRM1 qualitatively lowered tumorsphere formation compared to the EV line, but 
the differences were not significant.  This could be due to the low overall tumorsphere-forming capacity of 
the EV line.  Interestingly, the T232P mutant formed significantly more tumorspheres.  This suggests that 
the T232P mutant may not behave as a simple loss-of-function mutant, but may have neomorphic 
properties.  However, due to the low overall tumorsphere formation rates in these cells, we will perform 
subsequent tumorsphere experiments using the 786-O lines.  
Figure 3.2 – PBRM1 knockdown in 786-O increases tumorsphere-forming capacity.  A.) Tumorsphere-
forming capacity of 786-O lines, Left panel - # of tumorspheres formed initially (1st passage); Right panel - # 
of tumorspheres formed for control and PBRM1 shRNA #2 after dissociating cells from 1st passage and 
replating (2nd passage).  B.) Cell numbers at time of passaging for control and PBRM1 shRNA #2 lines. C.) 
Representative images of tumorspheres for control and PBRM1 shRNA cells, at 1st and 2nd passage.  Error 
bars represent SEM for n=5-6; unpaired t-tests were used for statistical testing. 
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Anchorage-independent growth in 786-O 
requires ALDH1-class enzyme activity 
Having established that PBRM1 
knockdown cells have increased tumorigenic 
potential as seen by colony formation in soft-
agar (Figure 2.6.) and tumorsphere-forming 
capacity and self-renewal (Figure 3.2), we 
next asked if ALDH1A1 contributed to this 
process.  We performed tumorsphere assays 
in the 786-O control and PBRM1 shRNA lines 
to which we added the ALDH1-class inhibitor 
DEAB (or 95% ethanol solution as a vehicle 
control) (Figure 3.4A, left panel).  We used 
the same concentration of DEAB that is used to set the negative baseline in the ALDEFLUOR assay 
(15uM).  The addition of DEAB almost completely abrograted the ability of either line to form 
tumorspheres, indicating that some level of ALDH1-class activity is required for tumorsphere formation.   
To demonstrate that this effect was due to ALDH1A1 inhibition specifically, we knocked down 
ALDH1A1 in each line using three different siRNAs (Figure 3.4B).  Like we saw with DEAB addition, 
ALDH1A1 knockdown reduced the ability of both lines to form tumorspheres (Figure 3.4A, right panel).  
The level of reduction, however, was not as dramatic as that seen with DEAB.  This suggests that either 
siRNA knockdown of ALDH1A1 is not as effective a means of blocking ALDH1A1 as DEAB addition, or 
that other ALDH1-class enzymes (ALDH1A2 or ALDH1A3) may be involved. 
To show that these effects were not specific to the tumorsphere assay, we also performed soft-
agar assays in which we titrated in higher doses of DEAB, up to the 15uM dose (Figure 3.4D).  We saw a 
dose-dependent inhibition of colony formation in the PBRM1 shRNA line.  At the highest dose of DEAB, 
an equally low number of colonies could form for the control and PBRM1 shRNA lines. 
Figure 3.3 – PBRM1 mutant T232P increases 
tumorsphere-forming capacity in A-704 cells.  
Tumorsphere-formation capacity of A-704 lines.  The 
differences between the EV and WT/1204P lines were not 
statistically significant. n=3/line; unpaired t-tests were 
used for statistical testing.   
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To rule out that the DEAB was killing the cells or inhibiting proliferation, we performed growth 
curve analysis on these lines with increasing doses of DEAB (Figure 3.4C).  Importantly, DEAB had no 
effects on 2-D cellular growth, even at 100uM.  Overall, these findings suggest that ALDH1-class activity 
is specifically required for anchorage-independent growth, whether measured by the tumorsphere or soft-
agar assays. 
 
ALDH1A1 overexpression increases tumorsphere-forming capacity 
 We next asked whether ALDH1A1 overexpression on its own could increase tumorsphere-
forming capacity.  In the 786-O control line, we transfected in either an empty-vector control plasmid, or a 
plasmid containing HA-tagged ALDH1A1.  Western blot analysis revealed successful overexpression of 
Figure 3.4 – Anchorage-independent growth in 786-O requires ALDH1-class enzyme activity.  A.) 
Tumorsphere assays in 786-O control and PBRM1 shRNA #2 lines.  Left panel – Vehicle control or DEAB (15uM) 
was added to the tumorsphere media at time of plating.  Right panel – Cells were transfected with non-targeting 
siRNA (C) or 1 of 3 ALDH1A1-targting siRNAs (#2, #5, or #7) 24hrs before plating for tumorsphere assay.  
n=3/condition; unpaired t-tests were used for statistical testing. B.) Western blot analysis of ALDH1A1 expression 
levels in same cells used for tumorsphere assay with ALDH1A1 siRNA knockdown at time of plating.  C.) Growth 
curve analysis, as measured by Incucyte ZOOM % confluence, of 786-O lines treated with increasing doses of 
DEAB or vehicle control.  n=3/dose at each timepoint. D.) Colony formation in soft-agar of 786-O control and 
PBRM1 shRNA #1 lines.  Increasing doses of DEAB, or vehicle control, were mixed in with the soft-agar at time of 
plating.  n=3/line at each dose, error bars represent SEM, and unpaired t-tests of the 0uM treated condition vs. 
higher doses within a cell line were performed. 
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the ALDH1A1-HA, although expression levels were still lower than the endogenous ALDH1A1 levels seen 
with PBRM1 knockdown (Figure 3.5, right panel).  Compared to the EV-control, ALDH1A1-HA 
overexpression nearly doubled the number of tumorspheres that formed (Figure 3.5, left panel).  This 
increased tumorsphere-forming capacity was still lower than that seen with PBRM1 knockdown, in line 
with the level of ALDH1A1 overexpression.   
 
PBRM1 deficiency increases sensitivity to EGF stimulation 
PBRM1 status affects total EGFR levels and downstream signaling 
 GSEA and gene ontology analysis of the RNA-seq data suggested that PBRM1 influences 
multiple pathways, including the EGFR pathway.  To test this, we placed the 786-O and A-704 lines in 
serum-free conditions, stimulated with EGF, and checked for differences in downstream signaling events.  
At serum-free conditions, the 786-O PBRM1 shRNA lines had much higher total EGFR levels (Figure 
3.6A).  These lines were also more sensitive to EGF stimulation compared to the control line: p-EGFR 
(Y1143) levels were elevated, as were p-AKT (T308) and p-ERK levels.  This differential sensitivity was 
most apparent at 20 ng/mL EGF stimulation.   In this cell line, p-AKT levels at S473 were similar.  In the 
Figure 3.5 – ALDH1A1 overexpression increases tumorsphere-forming capacity.  786-O 
control shRNA cells were transfected with either an empty-vector control plasmid (pcDNA-EV), or 
a plasmid expressing an HA-tagged ALDH1A1 (pcDNA-ALDH1A1-HA).  Right panel – Western 
blot analysis showing level of expression of ALDH1A1-HA, in comparison to EV-control 
transfected cells (left lane), or endogenous ALDH1A1 levels in the PBRM1 shRNA #2 line (right 
lane).  Left panel – tumorsphere formation in 786-O control cells transfected with the indicated 
plasmids.  n=3/line; an unpaired t-test was used for statistical testing.   
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A-704 lines, similar trends were evident (Figure 3.6B).  At baseline, expression of WT PBRM1 resulted in 
lower total EGFR levels compared to the EV control or PBRM1 mutant lines.  When stimulated with EGF, 
the WT line responded with lower levels of p-EGFR (Y1173), p-AKT (at both T308 and S473), and p-ERK, 
compared to the other lines.  In their responses, the PBRM1 mutant lines resembled the EV control. 
 
PBRM1 status affects growth responsiveness to EGF stimulation 
 Having seen differences in downstream signaling in response to EGF stimulation, we 
hypothesized that PBRM1 status would also affect how the cells grew in response to EGF.  To test this, 
we grew the cells at very low concentrations of serum (0.1% and 2.5% serum for 786-O and A-704, 
respectively), such that they didn’t die but only grew in a limited fashion.  Without EGF stimulation, the 
786-O PBRM1 shRNA lines grew slightly faster than the control line (Figure 3.7A – solid lines).  Likewise, 
the A-704 EV line had a slight growth advantage over the WT line (Figure 3.7B – solid lines).  When 
stimulated with EGF, both 786-O PBRM1 shRNA lines responded with faster growth; the control line, on 
the other hand, did not respond at all (dashed lines).  In the A-704 lines, EGF stimulation produced even 
Figure 3.6 – PBRM1 status affects total EGFR levels and downstream signaling.  A.) Western blot 
analysis of 786-O lines stimulated with the indicated concentration of EGF for 30’ under serum-free 
conditions.  B.) Western blot analysis of A-704 lines stimulated with 1ng/mL EGF for 30’ under serum-
free conditions.   
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more divergent outcomes: the EV line responded with a slight growth increase, while EGF stimulation had 
a growth inhibitory effect on the WT line (dashed lines).  An anti-growth EGF effect in seen in some cell 
lines (Barnes, 1982) (Xie et al., 1997) (Yamasaki et al., 2003), including sometimes for ccRCC (Ramp et 
al., 1997).   
 
PBRM1 knockdown in 786-O renders cells more resistant to EGFR inhibition 
 We next explored whether PBRM1 knockdown influences sensitivity to EGFR inhibition using the 
drug erlotinib.  Having established that PBRM1 knockdown has particularly large effects on 3-D growth, 
we tested how EGFR inhibition affected colony growth in soft-agar in the 786-O lines.  As expected, 786 
PBRM shRNA #1 cells formed significantly more colonies compared to control cells when treated with 
vehicle (Figure 3.8).  When treated with an intermediate dose of erlotinib (1uM), the control cells almost 
completely lost their ability to form colonies, while the knockdown cells still formed significantly more 
colonies, albeit at a reduced level.  At a higher dose of erlotinib (10uM), colony growth was severely 
limited in both lines. 
 
Decreased sensitivity to IFNα with PBRM1 deficiency 
PBRM1 deficiency reduces basal and IFNα-induced IFI27 mRNA levels 
Figure 3.7 – PBRM1 status affects growth responsiveness to EGF stimulation.  A.) 2-D growth curves of 
786-O lines grown on 48-well tissue culture plates at 0.1% serum in the presence of PBS (0 EGF, solid lines) or 
50 ng/mL EGF (50 EGF, dotted lines). B.) 2-D growth curves of A-704 lines grown on 48-well tissue culture plates 
at 2.5% serum in the presence of PBS (0 EGF, solid lines) or 10 ng/mL EGF (10 EGF, dotted lines).  n=6 per 
timepoint for each line. Two-way ANOVAs using Tukey’s multiple comparisons test was performed on each set of 
growth curves, and significant differences between the untreated and EGF stimulated condition for a given line 
are shown. * P<0.05; ** P<0.01; *** P <0.001; **** P<0.0001. 
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 Gene expression profiling of our cell 
lines at low serum suggested that interferon-
response pathways were also perturbed with 
PBRM1 alteration.  At both normal and 
reduced serum, one of the top downregulated 
genes with PBRM1 deficiency was IFI27, 
also known as Interferon, Alpha-Inducible 
Protein 27 or ISG12.  IFI27 is a thought to be 
a pro-apoptotic interferon-response gene that 
localizes to the mitochondrial membrane and 
can enhance cytochrome c release and 
apoptosis in conjunction with other pro-
apoptotic stimuli (Rosebeck and Leaman, 
2008) (Cheriyath et al., 2011).  Some reports 
have implicated IFI27 as a key mediator of TRAIL-induced apoptosis (Liu et al., 2014b) (Liu et al., 2014a).  
While decreased IFI27 levels have been found in some cancers (Mihalich et al., 2012), other studies have 
reported increased IFI27 levels (Suomela et al., 2004) (Wenzel et al., 2008).  In connection to the 
SWI/SNF complex, one previous study has linked IFI27 expression to the activity of BRG1 downstream of 
IFNα and STAT2 signaling (Huang et al., 2002), while another study saw no IFI27 dependence on ARID2 
(Yan et al., 2005). 
 To determine PBRM1’s relationship to IFN signaling and IFI27 induction, we treated the 786-O 
and A-704 lines with IFNα and measured IFI27 mRNA levels at various timepoints.  In agreement with the 
RNA-seq data, IFI27 mRNA levels were significantly lower at baseline in the 786-O shRNA #1 line and 
the A-704 EV line (Figure 3.9A and B).  When stimulated with IFNα, IFI27 mRNA levels rose dramatically 
in the 786-O control line, cresting at a nearly 80-fold induction at 24hrs (Figure 3.9A).  The 786-O PBRM1 
shRNA line was much less responsive at all time points.  IFI27 was not as highly induced in the A-704 
lines with IFNα stimulation, but WT PBRM1 expression still heightened the response (Figure 3.9B).  At all 
Figure 3.8 – PBRM1 knockdown in 786-O renders 
cells more resistant to EGFR inhibition.  Colony 
formation in soft-agar of 786-O control and PBRM1 
shRNA #1 lines.  Increasing doses of erlotinib, or vehicle 
control, were mixed in with the soft-agar at time of plating.  
n=3/line at each dose, error bars represent SEM, and 
unpaired t-tests using the Holm-Sidak method to correct 
for multiple comparisons between cell lines at a given 
dose were performed. 
54 
 
timepoints except 48hrs, IFI27 was induced to a higher degree in the WT line compared to the EV (at 
48hrs, there was a trend towards higher expression). 
 
IFI27 mRNA levels are lower in PBRM1 mutant tumors 
We next asked whether IFI27 expression changes could be seen in primary ccRCC tumors based 
on PBRM1 status.  We applied the same methodology we used in Chapter 2 (Figure 2.16).   In the TCGA 
dataset, IFI27 expression levels were significantly lower in PBRM1 mutant tumors (Figure 3.10), in line 
with our cell culture models.  However, in the Peña-Llopis et al dataset, IFI27 was not among the 
significant genes that distinguished PBRM1 mutant vs. non-mutant tumors. 
 
A-704 cells expressing PBRM1 are more growth inhibited by IFNα 
To test whether the differential response to IFNα had any functional consequences, we 
performed growth-curve analysis on the A-704 lines in the presence of increasing doses of IFNα.  The 
WT PBRM1 expressing line was more growth inhibited by IFNα – even the lowest dose of 10 units/mL 
slowed growth to some extent, while the higher doses (200 and 500 units/mL) almost completely inhibited 
Figure 3.9 – PBRM1 deficiency reduces basal and IFNα-induced IFI27 mRNA levels. qRT-PCR analysis of 
IFI27 mRNA levels (relative to GAPDH) in the 786-O (A) and A-704 (B) lines after treatment with 100 units/mL of 
IFNα for the indicated times. The delta-delta-Ct method was used to analyze the data, with timepoint 0hr for the 
786-O control shRNA and A-704 EV lines set to 1. Error bars represent standard deviations for n=3.  Unpaired t-
tests were performed comparing the control and PBRM1-altered lines at a given timepoint. * P<0.05; ** P<0.01; *** 
P <0.001; **** P<0.0001. 
55 
 
growth (Figure 3.11, right panel).  Meanwhile, 
10 units/mL had no effect on the EV line, and 
the highest doses slowed but did not halt 















Figure 3.10 – IFI27 mRNA levels are lower in PBRM1 
mutant tumors.  Provisional TCGA data for ccRCC was 
taken from the cBioPortal for Cancer Genomics in 
November 2015 – 417 tumor samples had sequencing 
and expression data available.  We divided the tumors 
into those with PBRM1 mutations (Mut) and those without 
(WT) – 122/417 tumors were mutated.  mRNA z-score 
levels are shown for IFI27 in the form of a Tukey plot with 
the outliers not shown.  Statistical testing was performed 
using the Mann-Whitney test. 
Figure 3.11 – A-704 cells expressing PBRM1 are more growth inhibited by IFNα. 2-D growth curves of A-704 
lines (EV, left, and WT, right) grown on 48-well tissue culture plates at full serum in the presence of the indicated 
doses of IFNα or vehicle control. Growth data was collected using an Incucyte Zoom machine as a % confluence 




In this chapter, we set out to confirm and further explore the connection between PBRM1 and 
some of the genes and pathways implicated from our gene expression analysis in Chapter 2.  First, we 
investigated PBRM1 regulation of ALDH1A1, a putative marker of tumor-initiating cells.  We verified via 
qRT-PCR that ALDH1A1 mRNA levels increased with PBRM1 deficiency in our cell culture systems, and 
that this translated into increased protein expression in our ccRCC lines (Figure 3.1).  We then went a 
step further and used the ALDEFLUOR assay to show that ALDH1-class enzyme activity increased with 
PBRM1 deficiency.   
We then demonstrated that this ALDH1A1 upregulation has functional consequences for 
tumorigenic potential.  In two different anchorage-independent growth assays (tumorsphere formation and 
colony formation in soft agar), we chemically inhibited ALDH1-class enzyme activity with DEAB and 
abrogated 3-D growth (Figure 3.4).  In the tumorsphere assay, this inhibition occurred in both the 786-O 
control and PBRM1 knockdown lines, indicating that PBRM1 knockdown cells had not become uniquely 
dependent on ALDH1-activity.  Instead, these findings imply that some minimal level of ALDH1-activity is 
required for anchorage-independent growth, and suggest more of a dose-response relationship, where 
having more ALDH1-activity translates into more 3-D growth.  The ALDH1A1 overexpression experiment 
in the control cells further supports this model, where higher expression of ALDH1A1 led to increased 
tumorsphere-forming capacity (Figure 3.5).  ALDH1-effects seem to be limited to anchorage-independent 
growth, as even very high doses of DEAB had no effect on 2-D growth on a plate.  
The overexpression experiment also indicated that this effect is specific to ALDH1A1, at least in 
part (versus ALDH1A2 or ALHD1A3).  Decreased tumorsphere formation with siRNA knockdown of 
ALDH1A1 provides additional evidence of an ALDH1A1-specific effect.  However, the level of 
tumorsphere inhibition with siRNA was not as great as with DEAB, suggesting either less effective 
inhibition of ALDH1A1 with siRNA, the involvement of other ALDH1-class enzymes, or off-target effects 
by DEAB.  While the RNA-seq analysis indicates that ALDH1A2 and ALDH1A3 mRNA levels did not 
change with PBRM1 alteration, future experiments could more definitively determine if they were 
contributing to 3-D growth processes in these cells. 
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 While our findings suggest that ALDH1A1 expression and activity are increased with PBRM1 
deficiency, and that this increases tumorigenic potential, we did not explore how ALDH1A1 could be 
mediating this effect.  Although prior studies offer some possible explanations, such as non-canonical 
retinoic acid signaling through PPARβ/δ, or increased protection from oxidative damage, we do not know 
what factors are involved in this setting.  Future experiments could investigate how ALDH1A1 increases 
tumorigenic potential in our ccRCC cell lines.  For example, the role of retinoic acid signaling could be 
further explored.  Total levels of retinoic acid (all-trans or cis) could be measured and compared in the 
minus- and plus-PBRM1 conditions.  The mRNA levels of known targets of canonical vs. non-canonical 
retinoic acid signaling could be quantified.  Retinoic acid receptor agonists and antagonists could be 
added to the anchorage-independent growth assays.  Other experiments could investigate the role of 
reactive oxygen species and oxidative protection by ALDH1A1. 
 Prior studies investigating SWI/SNF components have often found that they play wide-ranging 
roles in a cell – ChIP-seq and gene expression profiling experiments suggest that SWI/SNF complexes 
bind across the genome and modulate a multitude of genes and pathways (Ho et al., 2009) (Euskirchen 
et al., 2011).  We too have found this to be the case for PBRM1.  Our RNA-seq analysis suggested that 
PBRM1 was affecting the EGFR pathway, and we confirmed that in this chapter.  After EGF stimulation, 
we saw heightened downstream signaling and growth responsiveness in the lines with PBRM1 deficiency 
(Figures 3.6 and 3.7).  At baseline, these lines had dramatically higher total EGFR protein levels, 
providing a possible explanation for this increased sensitivity.  Based on the RNA-seq data, EGFR mRNA 
levels were also moderately increased, suggesting that this effect is at least partially transcriptional 
(normal serum RPKM values: 786-O control shRNA - 37 ; PBRM1 shRNA #1 - 50; PBRM1 shRNA #2 - 
58; A-704 EV - 205; A-704 WT - 178).  However, this does not rule out post-translational events, such as 
protein modification, altered EGFR cycling to the membrane, or reduced ubiquitination and proteosomal 
degradation.  Future experiments could discern why EGFR protein levels were increasing so much. 
These changes in EGFR signaling, however, did not translate into an “oncogene addiction,” at 
least for the 786-O cells.  When treated with erlotinib, the PBRM knockdown cells were more resistant to 
3-D growth inhibition – at the intermediate dose of erlotinib, they could still form colonies in soft agar, 
while the control cells had largely lost this ability (Figure 3.8). This suggests that EGFR inhibitors might 
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have better clinical efficacy in non-PBRM1 mutant tumors, an idea that could be further explored using 
tissue culture models and xenograft studies before being put to the test in the clinic. 
Lastly, we explored the connection between PBRM1 and IFN signaling suggested by the low-
serum RNA-seq analysis.  We found that PBRM1 deficiency lowered the induction of the reportedly pro-
apoptotic interferon response gene IFI27 with IFNα stimulation, and that expression of WT PBRM1 in A-
704 cells increased growth inhibition by IFNα (Figures 3.9 and 3.11).  In light of previous studies with 
mixed findings on SWI/SNF control of IFI27 induction (Huang et al., 2002) (Yan et al., 2005), our results 
suggest some degree of cell-type specificity in terms of what particular IFN response genes are SWI/SNF 
dependent.  For example, we saw no changes in IFITM1, the IFN response gene found to be ARID2 
dependent in Yan et al, 2005, in our RNA-seq analysis.  As reports describe IFI27 as promoting apoptosis 
in conjunction with other stimuli, such as DNA-damage or TRAIL-treatment, future experiments could 
measure how PBRM1 status affects apoptosis levels in response to some of these combinations (e.g., 
IFNα + TRAIL).  As IFN therapy is still widely used for the treatment of ccRCC, these findings have 
clinical implications and suggest that PBRM1 mutant tumors would be more resistant to IFN therapy.  
They also imply that PBRM1 status may impact therapeutic response to the emerging class of immune 
checkpoint therapies, as PBRM1 mutant tumor cells may be less susceptible to some of the death-
inducing mechanisms of newly activated T-cells.  It will be interesting to see if ccRCC patients that 
respond to immune-checkpoint therapy are enriched for non-PBRM1 mutant tumors. 
 In this chapter, we have confirmed that PBRM1 plays a role in the regulation of ALDH1A1 
expression, and the EGFR and IFN pathways, and that this has important functional consequences.  
However, we have not yet explored the molecular mechanisms through which PBRM1 could be exerting 













CHAPTER 4: With PBRM1 deficiency, ARID2 still binds in a SWI/SNF complex, but 





BACKGROUND AND SIGNIFICANCE 
 In Chapters 2 and 3, we examined genes and pathways regulated by PBRM1 that contribute to its 
tumor suppressor function.  So far, this analysis has treated PBRM1 more as a single protein that 
represses or activates transcription on its own.  However, when studying PBRM1, it is important to keep 
in mind that it is part of a multi-subunit complex, where loss of a single subunit could have complex 
effects on the remaining subunits’ assembly and action.  For example, SNF5 loss is only transforming 
when BRG1 is present, implying that aberrant SWI/SNF activity, but not the total lack of activity, is 
oncogenic (Wang et al., 2009).  A recently identified SWI/SNF complex member, SS18, also dramatically 
alters complex formation in cancer (Kadoch and Crabtree, 2013).  Numerous recent reports have also 
demonstrated a synthetic lethal relationship between homologous SWI/SNF subunits.  For example, two 
independent studies identified BRM as an essential gene in BRG1 mutant cancers (Hoffman et al., 2014) 
(Wilson et al., 2014).  ARID1A and ARID1B, mutually exclusive subunits in the BAF complex, exhibit a 
similar relationship (Helming et al., 2014b).  These studies indicate that some level of SWI/SNF activity 
may be essential for growth in cells, and suggest specific cancer vulnerabilities that could be targeted 
therapeutically.  
It has previously been shown that, at least in some cell lines, PBRM1 is not required for PBAF 
complex assembly (Yan et al., 2005).  In HCC1143 cells, a breast cancer line where PBRM1 is not 
expressed, ARID2 was expressed and was still capable of associating in a complex with other SWI/SNF 
components.   In HeLa cells, ARID2 was required for PBAF complex assembly – without it, the complex 
fell apart and PBRM1 was degraded.  However, the reverse was not true – PBRM1 knockdown did not 
cause a reciprocal decline in ARID2 levels. These findings suggest that a PBAF-like complex remains 
even after PBRM1 loss.  
In this chapter, we will explore how PBRM1 deficiency in ccRCC impacts some of the remaining 
subunits of the PBAF complex, such as ARID2.  In doing so, we hope to better understand the molecular 
mechanisms that lead to some of the transcriptional changes previously described. 
 
RESULTS 
PBRM1 deficiency increases ARID2 protein levels 
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 We first asked how PBRM1 deficiency impacts the protein levels of some of the remaining PBAF 
subunits in our cell line systems.   In 786-O cells, PBRM1 knockdown led to a large increase in ARID2 
protein levels (Figure 4.1A).  SNF5 protein levels also increased in both PBRM1 shRNA lines.  In the A-
704 cells, stable expression of WT PBRM1 resulted in lower ARID2 protein levels, whereas levels 
remained stable with expression of PBRM1 cancer-associated mutants.  SNF5 levels did not differ among 
the A-704 lines.  Also, in both 786-O and A-704 lines, BRG1 levels did not change consistently. 
 We also checked PBAF-subunit protein levels in ACHN cells (Figure 4.1B).  PBRM1 knockdown 
led to even more dramatic increases in ARID2 protein levels.  SNF5 levels did not change consistently 
between the PBRM1 hairpins, and BRG1 levels remained stable.  We concluded that PBRM1 deficiency 
results in increased protein levels of ARID2. 
 
Increased ARID2 levels are at least partially due to increased transcription 
 To see if these ARID2 changes happened at the mRNA level, we performed qRT-PCR analysis in 
the 786-O and A-704 lines.  As we saw at the protein level, PBRM1 knockdown in the 786-O cells led to 
increased ARID2 mRNA levels, while WT PBRM1 expression in A-704 cells led to decreased mRNA 
levels (Figure 4.2A).   While these mRNA changes were modest, they suggest that increased ARID2 
levels are at least partially due to increased transcription. 
 
  
Figure 4.1 - PBRM1 deficiency increases ARID2 protein levels.  Western blot analysis of the indicated 
PBAF complex components in 786-O and A-704 (A) and  ACHN cell lines (B). 
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We next asked whether we could see similar changes in ccRCC primary tumors using the publicly 
available datasets.  In both datasets, PBRM1 mutation was associated with significantly higher ARID2 
mRNA levels (Figure 4.2B). 
 
In the absence of PBRM1, ARID2 still associates with SWI/SNF components 
Having seen increased ARID2 levels with PBRM1 knockdown, we next tested whether this ARID2 
was assembling into a SWI/SNF complex.  We performed immunoprecipitation (IP) experiments using an 
antibody against BRG1 and checked for binding of ARID2, SNF5, and PBRM1.  In the 786-O cells, high 
levels of ARID2 still bound to BRG1 after PBRM1 knockdown (Figure 4.3A).  Similarly, in the A-704 cells, 
ARID2 still bound to BRG1, even in the absence of PBRM1 (the EV line) (Figure 4.3B).  These results are 
in agreement with previous studies that found that PBRM1 was dispensable for the rest of the PBAF 
complex assembling (Yan et al., 2005).   
While these IP experiments indicated that some ARID2 still associated with other SWI/SNF 
components, they did not preclude the possibility that ARID2 was binding to other proteins outside the 
PBAF complex.  We performed glycerol gradient fractionation experiments in the 786-O lines to determine 
if this was the case.  If ARID2 was binding outside of the PBAF complex, we would expect to see some of 
Figure 4.2 - Increased ARID2 levels are at least partially due to increased transcription. A.) qRT-PCR 
analysis of ARID2 mRNA levels (relative to GAPDH) in the indicated cell lines. Error bars represent 
standard deviations for n=3, the delta-delta-Ct method was used to analyze the data, with 786-O control 
shRNA and A-704 EV lines set to 1, and unpaired t-tests were performed.  B.) Provisional TCGA data for 
ccRCC was taken from the cBioPortal for Cancer Genomics in November 2015 – 417 tumor samples had 
sequencing and expression data available (mRNA z-scores). ccRCC expression data was also taken from 
Peña-Llopis et al (relative mRNA expression levels). We divided the tumors into those with PBRM1 
mutations (Mut) and those without (WT) – in the TCGA data,122/417 tumors were mutated, while 21/53 
tumors had PBRM1 mutations in Peña-Llopis et al. ARID2 levels are shown in the form of Tukey plots with 
the outliers not shown.  Statistical testing was performed using the Mann-Whitney test. 
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it eluting in fractions separate from other SWI/SNF subunits.  Based on published reports of glycerol 
gradient fractionation of SWI/SNF complexes, we used a 10-30% glycerol gradient, and spun for 18 hours 
to ensure good separation of lower molecular weight complexes where we hypothesized ARID2 might be 
relocating (Lessard et al., 2007) (Kadoch and Crabtree, 2013).  Looking from fractions 2-24 in the control 
cells (out of 24 total fractions), ARID2 eluted in the heavier fractions, mostly in fraction 2, with some 
protein in fractions 4 and 6 (Figure 4.4A-left panel).  PBRM1 showed the same pattern.  BRG1 and SNF5 
were found at slightly lighter fractions, both peaking in fraction 4 and extending to fraction 8.  
In both PBRM1 knockdown lines, there were subtle shifts in the elution pattern (Figure 4.4A – 
middle and right panels).  ARID2 now peaked in fraction 4, a slightly lighter fraction.  Likewise, the peaks 
of BRG1 and SNF both shifted to a slightly lighter fraction, fraction 6.  With these shifts, there was now 
more overlap between ARID2 and BRG1 and SNF5, indicating that with PBRM1 deficiency ARID2 could 
be more bound in SWI/SNF complexes.  Additionally, no ARID2 was found in lighter fractions without 
Figure 4.3 – In the absence of PBRM1, ARID2 still associates with SWI/SNF components. 
BRG1 IP experiments were performed on 0.5mg of protein from nuclear extracts of 786-O (A) and 
A-704 (B) cell lines.  A matched isotype IgG was used for control IPs.  Inputs are aliquots taken 
from pre-cleared nuclear extracts before the IPs were performed. 
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BRG1 and SNF5, suggesting that it was not binding in new complexes.  As expected, PBRM1 levels were 
barely detectable but when visible displayed the same pattern as the control cells. 
Because we did not see ARID2 in lighter fractions, we also looked at ARID2 elution patterns at 
higher resolution in the heavier fractions (Figure 4.4B).  In the control cells, ARID2 could be found in 
fractions 1-5, but peaked in fraction 1.  BRG1 and SNF5 were found mostly in fractions 4-6.  These 
results imply that the majority of ARID2 is found outside the PBAF complex in the control cells.  After 
PBRM1 knockdown, ARID2 shifted to lighter fractions, and could be found in fractions 2-6, peaking in 
fractions 4-5.  BRG1 and SNF also shifted to slightly lighter fractions, and could now be found in fractions 
4-7, with peaks in fraction 5.  Overall, these results support the IP findings and suggest that after PBRM1 
knockdown, more ARID2 is bound in a PBAF-like complex that also contains BRG1 and SNF5.  This 
complex elutes in slightly lighter fractions, perhaps reflecting the loss of PBRM1 inclusion. 
Subcellular fractionation experiments reveal that ARID2 increases in both the soluble and 
insoluble nuclear fractions 
 As the IP and glycerol gradient experiments were both performed on the soluble nuclear fraction 
of the 786-O cells, we next performed subcellular fractionation experiments to see if ARID2 was transiting 
to other cellular compartments (Figure 4.5).  We used tubulin (TUBB) as a cytosolic marker, MYC as 
Figure 4.4 – Glycerol gradient fractionation of 786-O cell lines. For each cell line, glycerol gradients were 
made using 10% and 30% glycerol solutions, to a total volume of 11.5 mL. Nuclear extracts of the 786-O 
lines were collected, they were diluted to 1.7mg/mL, and 0.5 mL was carefully layered on top of the glycerol 
gradients.  The gradients were spun for 18 hrs in a swinging bucket rotor in an ultracentrigure, and 0.5 mL 
fractions were collected from the bottom (heavier fractions) of the tube (24 fractions total).  Aliquots of the 
fractions were combined with 2x sample buffer and subjected to Western Blot analysis.  A.) Wider view of the 
fractionation, from fractions 2-24, skipping every other fraction, except in the middle. B.) Higher resolution 
analysis of the heavy fractions, fractions 1-10. 
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marker of both the soluble and insoluble nuclear fractions, and lamin B1 (LMNB1) and H3 as markers of 
the insoluble nuclear fraction.  Before being knocked down, PBRM1 could be found in both the soluble 
and insoluble nuclear fractions, as could ARID2.  With PBRM1 knockdown, ARID2 levels increased in 
both the soluble and insoluble nuclear fractions.  Additionally, after PBRM1 knockdown, less SNF5 
seemed to locate to the insoluble nuclear fraction.  No BRG1 could be detected in the insoluble nuclear 
fraction in any line.  No SWI/SNF component could be found in the cytoplasmic fraction. 
Along with the IP and glycerol gradient findings, these data suggest that after PBRM1 
knockdown, some ARID2 still associates with SWI/SNF components in the soluble nuclear fraction, while 
other ARID2 protein transits to the insoluble nuclear fraction, perhaps outside of the SWI/SNF complex.  
More experiments are needed to clarify the role of ARID2 in the insoluble nuclear fraction. 
 
 
Figure 4.5 – Subcellular fractionation of the 786-O lines.  786-O cells 
were subjected to subcellular fractionation to separate the cytosolic and 
nuclear fractions.  The insoluble nuclear fraction was resuspended in 2x 
sample buffer, subject to brief sonication, and boiled for 15 minutes to be 




ARID2 ChIP-seq indicates altered genomic binding of the PBAF complex that remains after 
PBRM1 knockdown 
After PBRM1 knockdown, ARID2 binds to fewer areas of the genome 
 Based on its domain structure and the fact that it’s one of the defining subunits of the PBAF 
complex, PBRM1 has been proposed to be a “targeting” SWI/SNF subunit, helping direct the complex to 
particular genomic loci.  Because of this and our finding that a PBAF-like complex containing ARID2 
remained intact after PBRM1 knockdown, we decided to probe the genomic binding of ARID2 before and 
after PBRM1 knockdown by performing ARID2 chromatin immunoprecipitation followed by sequencing 
(ChIP-seq) in the 786-O lines.  If PBRM1 was serving as a “targeting” subunit, we would expect to see 
altered ARID2 genomic binding after PBRM1 knockdown.  
 We used 75bp single-end sequencing on our ChIP-seq libraries, and achieved good depth of 





We aligned our reads using Bowtie 2 (Langmead and Salzberg, 2012), and then visualized the read pile-
ups on the UCSC genome browser.  In general, the binding profiles were broad and seemed to resemble 
wide binding domains rather than sharp peaks, similar to the profile seen for some histone marks, such 
as H3K27Me3.  Looking at the input DNA, serving as controls, we saw no such patterns.  For this reason, 
we decided to call peaks using SICER, which was designed to recognize and call disperse ChIP-enriched 
regions with high sensitivity and specificity (Zang et al., 2009).  We also used SICER to call differentially 
enriched regions between the samples. 
 First, we looked at the broad binding patterns of ARID2 across the genome.  There was a general 
loss of ARID2 binding with PBRM1 knockdown: 21,704 peaks were called in the control line, while only 
9,161 and 5,456 peaks were called in the PBRM1 shRNA #1 and #2 lines, respectively (Figure 4.6A).  We 
used HOMER to annotate the genomic feature (e.g., intron, exon, TSS) most closely associated with 
 
ChIP-seq depth of coverage 
(million reads): 
786-O Line ARID2 INPUT 
Control shRNA 28.6 33.5 
PBRM1 shRNA #1 32.4 28.6 
PBRM1 shRNA #2 23.2 29.6 




each called peak (Heinz et al., 2010).  Looking across the lines, we saw subtle shifts in the genomic 
regions associated with ARID2 peaks (Figure 4.6A).  With PBRM1 knockdown, ARID2 was proportionally 
slightly more bound to intergenic regions, and slightly less bound to intronic, promoter, and 5UTR regions.  
Overall, although these shifts were small, they were significantly different via the Chi-square test.  More 
strikingly, absolute numbers of ARID2 peaks decreased at every genomic feature with PBRM1 
knockdown (Figure 4.6B).  We also used SICER to identify regions with differential ARID2 binding 
depending on PBRM1 status.  Many more ARID2 peaks were lost than gained in both PBRM1 hairpin 
lines compared to the control (Figure 4.6C). 
To confirm that SICER was accurately calling ARID2 peaks and differential regions between the 
samples, we looked at the average binding enrichment profiles for the regions of differential binding called 
by SICER (Figure 4.7).  There were four sets of regions of differential binding: regions with gained ARID2 
peaks in the PBRM1 shRNA #1 or #2 lines; and regions with lost ARID2 peaks in the PBRM1 shRNA #1 
Figure 4.6 – Genomic annotation of ARID2 binding in 786-O lines.  HOMER was used to annotate the genomic 
feature most closely associated with each called peak in the 786-O lines. A.) Pie charts of the distribution of ARID2 
binding across genomic features.  Those features associated with 0 peaks in all lines are not shown.  The absolute 
numbers of peaks associated with each feature are shown in the legends, including the total number of called 
peaks. B.) Intra-line comparison of genomic annotation of ARID2 peaks in 786-O cells – the y-axis is in log-scale. 
C.) Table of number of gained and lost ARID2 peaks in the PBRM1 shRNA lines vs. the control, called by SICER. 
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or #2 lines.  When we looked at the average binding enrichment for each cell line at these genomic 
locations, we saw that differential peaks were accurately being called.  The lost peak regions for both 
PBRM1 hairpins produced sharp binding enrichment profiles only in the control sample (left panel), while 
the gained peak regions produced binding enrichment peaks only in the corresponding hairpin line 
(middle and right panels).  Additionally, there does not appear to be much overlap in the differential 
ARID2 peaks between the two PBRM1 hairpin lines, as the gained peak regions for one hairpin did not 
show an enrichment in the other hairpin line. 
 
k-means clustering of ARID2 binding enrichment reveals broad shifts in binding patterns with PBRM1 
knockdown 
 While our analysis so far indicated a general loss of ARID2 binding to the genome with PBRM1 
knockdown, we were curious whether this occurred at a subset of genomic regions, or whether there was 
broader shift in binding patterns.  To answer this question, we performed k-means clustering analysis on 
the ARID2 binding enrichment in the control sample.  We limited the analysis to the genomic locations (+/- 
2kb) of only the transcribed genes in 786-O, as defined in Chapter 2.  We set cluster number (k) equal to 
5, because at higher k’s the binding enrichment profiles became more finely segmented but did not differ 
Figure 4.7 – ARID2 binding enrichment profiles for ARID2 peaks gained or lost with PBRM1 
knockdown.  SICER was used to call ARID2 ChIP-seq binding peaks, and to identify regions of differential 
binding between the control line and the PBRM1 shRNA lines. The average ARID2 binding enrichment for 
each line for these differential regions was then generated using Galaxy’s deepTools.  The plots illustrate the 
average binding enrichment from 5kb upstream to 5kb downstream of the peak center.  All gained or lost 
peaks were in the PBRM1 shRNA line (#1 or #2) compared to the control line.  The numbers in parenthesis are 
the number of gained or lost peaks. 
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in the general pattern seen at 5 clusters.  As shown in Figure 4.8A, the clustering analysis produced 
clusters of regions with distinct ARID2 binding enrichment profiles: cluster 1 had high overall binding 
enrichment, with both upstream and downstream peaks; cluster 2 regions were defined by a sharp peak 
about 1000 kb upstream of the transcriptional start site (TSS); cluster 3 had a sharp binding peak 
immediately before the TSS; cluster 4 regions were distinguished by peaks downstream of the 
Figure 4.8 – k-means clustering of ARID2 binding enrichment in 786-O control cells.  Using Galaxy’s 
deepTools, we performed k-means clustering of the ARID2 binding enrichment in the 786-O control cells.  K 
was set equal to 5, and we looked at the regions surrounding all transcribed genes (+/- 2kb) in the 786-O cells, 
as defined by the RNA-seq analysis in Chapter 2. A.) Left panel - average binding enrichment for the 5 clusters 
identified in the control cells.  The same cluster sets were then applied to the PBRM1 shRNA ARID2 ChIP-seq 
results (right panels). B.) Tukey plots (with outliers shown) of the expression changes for the genes in each 
cluster defined in (A).  One-way ANOVA with multiple comparisons correction statistical testing was performed 
between the clusters. C.) Gene ontology analysis showing the top 12 enriched biological processes for the 
genes comprising Clusters 3 and 4. TSS=transcriptional start site; TES=transcriptional end site. 
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transcriptional end site (TES); and cluster 5 was defined by low binding with no peaks. When we applied 
these clusters to the PBRM1 shRNA lines, there was a general loss of binding patterns across all clusters 
(Figure 4.8A – right panels).  This suggests that in addition to ARID2 binding less to the genome, there is 
a broad shift in where it does bind after PBRM1 knockdown. 
 We also wondered whether there were any gene expression differences between the clusters.  
We used the log2(fold-change) values from the normal serum 786-O RNA-seq analysis to test this 
(PBRM1 shRNA/control shRNA fold-change values).  Although we did not see dramatic differences, 
clusters 3 and 4, defined by sharp peaks immediately upstream and downstream of genes, respectively, 
had significantly higher gene expression changes compared to cluster 5, defined by low overall binding 
enrichment (Figure 4.8B).  This means that in the control cells, genes in clusters 3 and 4 are being more 
repressed (i.e., with PBRM1 knockdown, they become more upregulated).  Gene ontology analysis of the 
genes in these clusters revealed that they are enriched for genes related to RNA splicing, DNA repair, cell 
cycle progression, and ribonucleoprotein complex assembly (Figure 4.8C). 
 Having thus far seen a general loss of ARID2 binding in the PBRM1 shRNA lines, we wanted to 
check if there were some regions with binding enrichment in these lines.  Clustering analysis of the 
PBRM1 shRNA lines revealed that regions could be clustered based on ARID2 binding enrichment in 
these lines as well (Figure 4.9A and B).  In fact, the clusters had enrichment profiles that were remarkably 
similar to the control line clusters.  However, the clusters generated consisted of entirely different sets of 
regions, as evident by the results when these clustering solutions were applied to the other lines.  The 
PBRM1 shRNA #1 clusters produced flat profiles in the control and shRNA #2 lines, and the PBRM1 
shRNA #2 clusters did the same in the control and PBRM1 shRNA #1 lines.  These results indicate that 
some ARID2 still binds to the genome after PBRM1 knockdown, but in broadly shifted patterns.  The low 
level of overlap in binding enrichment between the two PBRM1 shRNA lines (Figures 4.7 and 4.9) 




ARID2 binding differences correlate with gene expression changes 
The clustering analysis suggested that there might be an association between ARID2 binding 
patterns and gene expression changes.  To further explore this relationship, we plotted the average 
ARID2 binding score for each cell line for groups of genes with different expression changes (Figure 
4.10A).  For the genes that are most upregulated (top quartile) with PBRM1 knockdown, there was a peak 
of ARID2 binding immediately preceding the TSS in the control line (left panel).  In the PBRM1 shRNA #1 
line, this peak is lost, and in the shRNA #2 line, it is greatly diminished.  For the genes that are most 
downregulated (bottom quartile) with PBRM1 knockdown, similar changes were visible: in the control 
cells, there is a peak of ARID2 binding preceding the TSS, which is lost or greatly reduced with PBRM1 
Figure 4.9 – k-means clustering of ARID2 binding enrichment in 786-O PBRM1 shRNA lines.  Using 
Galaxy’s deepTools, we performed k-means clustering of the ARID2 binding enrichment in the 786-O 
PBRM1 shRNA lines.  K was set equal to 5, and we looked at the regions surrounding all transcribed genes 
(+/- 2kb) in the 786-O cells, as defined by the RNA-seq analysis in Chapter 2. A.) Left panel - average 
binding enrichment for the 5 clusters identified in the PBRM1 shRNA #1 cells.  The same cluster sets were 
then applied to the PBRM1 control and shRNA #2 ChIP-seq results (right panels). B.) Left panel - average 
binding enrichment for the 5 clusters identified in the PBRM1 shRNA #2 cells.  The same cluster sets were 
then applied to the PBRM1 control and shRNA #1 ChIP-seq results (right panels). 
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knockdown (middle panel).  The downregulated genes also have an ARID2 binding plateau in the region 
downstream of the TES in the control cells which is largely lost with PBRM1 knockdown.  As a control, we 
looked at the average binding profile among genes that we classified as unexpressed in the 786-O lines 
(right panel) (see Chapter 2 for explanation).  Although there was lower average binding in general for the 
PBRM1 shRNA lines, no cell line displayed peaks of binding for this set of genes.  As an additional 
control, we performed the same analysis on the input DNA for these gene sets and saw no peak patterns 
or major differences between the cell lines (Figure 4.10B). 
As an alternative method to assess how ARID2 binding changes impacted gene expression, we 
used the publicly available software package BETA (Binding and Expression Target Analysis) (Wang et 
al., 2013).  BETA makes predictions about the regulatory potential of a binding factor on a certain gene 
based on the level of binding around that gene, taking into account all binding sites within a certain 
distance from the TSS and their relative distances, and gene expression changes.  It ranks genes based 
on the regulatory potential of factor binding and on differential gene expression, and then calculates the 
rank product (used as a p-value) to predict direct gene targets.  It also ascertains whether factor binding 
Figure 4.10 –ARID2 and input DNA average binding profiles for the top upregulated, top downregulated, and 
unexpressed genes. A.) The average ARID2 binding score for each 786-O line was generated using Galaxy’s 
deepTools for the top quartile of upregulated genes (left panel), the top quartile of downregulated genes (most 
downregulated – middle panel), and genes that did not meet our threshold for expression (summed RPKM<10) 
(right panel).  The plots illustrate the average binding score from 2kb upstream of the TSS to 2kb downstream of the 
TES.  B.) As controls, the same plots as in (A) for the average input DNA scores. 
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upregulates and/or downregulates genes using a non-parametric statistical test comparing the binding 
factor regulatory potentials for genes that are differentially expressed versus those that don’t change. 
 We used the 786-O Cuffdiff output from the RNA-seq analysis as the gene expression input file 
(see Chapter 2).  As binding region inputs, we separately used the four different gained or lost ARID2 
peak files from Figure 4.7.  Using the ARID2 differential peak files separately would allow us to discern 
how ARID2 gain or loss contributed to gene expression changes.  The BETA activating/repressive 
function predictions of ARID2 peak changes are shown in Figure 4.11. The blue and red lines represent 
the upregulated and downregulated genes, respectively, from the 786-O RNA-seq analysis. The dashed 
line represents the genes whose expression did not change, which served as a background for 
comparison.  Genes are ranked based on the regulatory potential score of ARID2 binding, from high to 
low, and are then cumulated for the different expression sets – the quicker the genes cumulate, the 
sharper the rise of the curve, implying more of an association between ARID2 binding and the specified 
expression change.  The P values represent the significance of the upregulate or downregulate gene set 
distributions as compared to the background set by the Kolmogorov-Smirnov test. 
The results reveal that ARID2 peak changes are significantly correlated with gene expression 
changes – in all four ARID2 peak datasets, upregulated and downregulated genes accumulated more 
rapidly than static genes.  The data also indicate that ARID2 binding loss or gain can lead to both 
increased and decreased gene expression, suggesting that additional factors may be involved in 
determining the direction of expression changes, such as the histone modification context or presence of 
co-factors.  For both PBRM1 hairpins, there was a slightly stronger association between losing ARID2 
peaks and differential expression, particularly upregulation (Figure 4.11A and B, left panels).  This may 
reflect the fact that significantly more ARID2 peaks were lost than gained with PBRM1 knockdown.  For 
this reason, we were particularly interested in some of the putative direct gene targets that lose ARID2 
binding and have increased expression.  The top 50 of these genes from the BETA output are shown for 
each hairpin in Figure 4.12.  Among this set, we see many genes relevant to cancer, including some that 
we had already noted in our RNA-seq meta-analysis, such as EGFL7, CA2, ID1, and JAG1 (Figure 2.11).  
Although ALDH1A1 was not among the top 50 genes, it too was identified as a direct target gene in the 




Figure 4.11 – BETA analysis of ARID2 binding changes and differential expression.  The publicly available 
software program BETA (Binding and Expression Target Analysis) was used to assess the association between 
ARID2 binding changes and differential gene expression.  The 786-O Cuffdiff output from the RNA-seq analysis 
was used as the differential gene expression input file, and the ARID2 peaks gained or lost from Figure 4.6 were 
used separately for the binding region inputs.  The BETA activating/repressive function prediction of ARID2 peak 
changes for the PBRM1 shRNA #1 line (A) and shRNA #2 line (B) are shown. The blue and red lines represent 
the upregulated and downregulated genes, respectively, from the 786-O RNA-seq analysis. The dashed line 
represents the genes whose expression did not change, which served as a background for comparison.  Genes 
are ranked based on the regulatory potential score of ARID2 binding, from high to low, and are then cumulated 
for the different expression sets – the quicker the genes cumulate, the sharper the rise of the curve, implying 
more of an association between ARID2 binding and the specified expression change.  The P values (in 
parentheses) represent the significance of the upregulate or downregulate gene set distributions as compared to 




Figure 4.12 – BETA-identified direct 
gene targets that lose ARID2 binding 
and have increased gene expression 
with PBRM1 knockdown.  The top 50 
BETA-identified direct gene targets that 
lose ARID2 binding (DECREASED peaks) 
and have increased gene expression 
(upregulate) in each PBRM1 shRNA line 
(#1 – left table; #2 – right table).  The 
genes are ordered by the rank product, 
which BETA uses as a p-value. 
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ARID2 binding patterns at specific loci 
 We next looked at the ARID2 peak patterns around some of these genes using the UCSC 
genome browser (Figure 4.13).  ARID2 binding enrichment levels (compared to input DNA) for all peaks 
(FDR<0.05) are shown.  Around the ALDH1A1 locus, ARID2 binding patterns shift with PBRM1 
knockdown (Figure 4.13A).  In the control cells, ARID2 peaks can be found both upstream (~60kb) and 
downstream (~35kb) of the gene TSS and TES, respectively.  With PBRM1 knockdown, these peaks 
seems to relocate closer to the gene body, and can be found around the TSS and within the gene body 
for shRNA #2.   
Broad shifts in ARID2 binding can also be seen around the EGFR and CA2 loci (Figure 4.13B 
and C, respectively).  ARID2 seems to bind widely around the EGFR locus in the control cells – peaks 
can be found upstream, at the TSS, in the gene body, and downstream of the TES.  With PBRM1 
knockdown, many of these peaks are lost, and the bound ARID2 that remains can be found mostly in the 
gene body.  At the CA2 locus, ARID2 enriches around and downstream of the TES in the control cells.  In 
the PBRM1 knockdown cells, many of these downstream peaks are lost, particularly for shRNA #2. 
 For other genes, ARID2 appears bound around the TSS when PBRM1 is present.  When PBRM1 
is lost, ARID2 binding at the TSS is concomitantly lost.  ID1, JAG1, and EGFL7 display this pattern of 
binding (Figure 4.13D-F, respectively). 
 Lastly, for some genes with differential expression, such as ARID2 and IFI27, there was no 
detectable ARID2 binding around the gene locus in any line (Figure 4.13G and H, respectively).  This 
pattern of binding suggests that these genes may not be under direct transcriptional control by PBRM1, 
but instead may be affected through indirect means. 
 In total, these snapshots of ARID2 binding support our conclusions that ARID2 binding is broadly 





















PBRM1 knockdown results in widespread increases in H3K4 trimethylation 
 As SWI/SNF mutation in cancer has previously been noted to result in altered histone 
modifications, we also performed ChIP-seq on various histone marks in the 786-O lines to assess 
whether PBRM1 knockdown changed the histone landscape.  We performed native ChIP-seq for these 
studies, where the cells are not fixed and mononucleosomes are isolated via the action of micrococcal 
nuclease.  This method is thought to yield higher resolution mapping of histone modifications on single 
nucleosomes and to avoid non-specific signal from modifications on nearby or linked nucleosomes 
(Schones et al., 2008) (Cuddapah et al., 2009).  We probed for the following marks: H3K4Me3, a marker 
H. 
Figure 4.13 - ARID2 binding patterns at specific loci.  ARID2 binding enrichment levels (compared to input 
DNA) for all peaks (FDR<0.05) at specific loci, as visualized on the UCSC genome browser.  For a specific gene, 
the scales of binding enrichment have been set equal to each other across all lines.  ARID2 binding around the 




of active promoters; H3K4Me1, a marker of enhancers; H3K27Ac, a marker of active enhancers and 
promoters; H3K27Me3, a repressive mark; and H3K9Ac, a marker of active enhancers and promoters. 
 We aligned our results with Bowtie 2 and performed peak-calling with MACS2 (Zhang et al., 
2008).  To get an overall picture of histone mark changes with PBRM1 knockdown, we used the MACS2 
tool bdgdiff, which identifies common, gained, and lost peaks between samples.  For this analysis, we 
treated the two PBRM1 shRNA lines as replicates and compared them to the control line.  The results are 
shown in Table 4.2, where the absolute number of common, gained, or lost peaks are listed.  There was a 
striking gain of H3K4Me3 peaks with PBRM1 knockdown (31,155 peaks), while 0 peaks were lost.  There 
was also a notable loss of H3K4Me1 and H3K9Ac peaks, with very few gains.  For the H3K27Ac and 
H3K27Me3 marks, very few gains or losses occurred with PBRM1 knockdown. 
 Peaks 
Mark Common Gained Lost 
H3K4Me3 2,067 31,155 0 
H3K4Me1 78,151 515 9,987 
H3K27Ac 1,906 8 151 
H3K27Me3 8,087 138 122 
H3K9Ac 16,472 1 1,029 
 We next asked how relevant these histone mark changes were to differential gene expression in 
these cells.  We ran BETA again, using the gained or lost peak files for each histone mark as the binding 
factor datasets.  Gained H3K4Me3 peaks were highly associated with expression changes (Figure 
4.14A).  Interestingly, both upregulated and downregulated genes showed this association (P=2.58e-128 
and P=9.51e-184, respectively).  As H3K4Me3 is traditionally associated with active transcription and 
increased gene expression, these results suggest the involvement of other factors that could further 
shape expression outcomes, such as the binding of inhibitory co-factors.   H3K4Me3 loss could not be 
investigated because there were no lost peaks. 
 Additionally, H3K4Me1 lost peaks were significantly associated with downregulated genes (Figure 
4.14B).  As this mark is traditionally associated with enhancers, its loss would be expected to result in 
decreased gene expression.  For all the other marks, peak changes showed no correlation with 
Table 4.2 – Number of peak changes identified by 




differential expression in this system (Figure 4.15A-C).  H3K9Ac gain could not be probed because there 
was only 1 gained peak.  
 As changes in H3K4Me3 and H3K4Me1 seem to be the most relevant with PBRM1 knockdown in 
these cells, we next looked at the top target genes with changes in these marks (gains for H3K4Me3, and 
losses for H3K4Me1) and differential expression (Figure 4.16).  Among the upregulated genes with 
H3K4Me3 gains, we saw many previously noted genes, including CA2, ID1, JAG1, and ALDH1A1.   
 We next looked at the H3K4Me3 levels at the TSS of ALDH1A1, CA2, ID1, and JAG1 (Figure 
4.17A-D, respectively).  H3K4Me3 binding enrichment levels (compared to input DNA) are shown.  For 
these genes, the control cells were not devoid of H3K4Me3 binding, but instead had H3K4Me3 
enrichment at the TSS.  PBRM1 knockdown led to a strengthening of this signal, and/or extension into the 
gene body.  These changes are particularly apparent for ALDH1A1 and CA2: for ALDH1A1, the signal is 
both strengthened at the TSS and the H3K4Me3 mark extends further into the gene body; while for CA2, 
the level of H3K4Me3 is actually decreased at the TSS, but extension is increased.  The expression 
values from the RNA-seq analysis show similar patterns of change: these genes are expressed in the 
control cells, but expression is enhanced following PBRM1 knockdown. 
 
ARID2 is required for some of the pro-tumorigenic effects of PBRM1 deficiency 
ALDH1A1 upregulation with PBRM1 deficiency requires ARID2 
 Having seen ARID2 upregulation and continued association with SWI/SNF components in 
PBRM1 deficient settings, but with altered genomic binding, we next asked what role ARID2 played in the 
pro-tumorigenic changes we previously associated with PBRM1 loss.  When we knocked down ARID2 
using three different siRNAs in the 786-O shRNA #1 cells, ALDH1A1 protein expression was no longer 
detectable (Figure 4.18A).  In the control cells, the little ALDH1A1 protein visible also disappeared with 
ARID2 knockdown.  PBRM1 protein levels declined after ARID2 knockdown in these cells, confirming 
previous findings that ARID2 is required for PBAF-complex stability.  We confirmed that the ALDH1A1 
changes were happening at the mRNA level (Figure 4.18B).  We saw similar declines in ALDH1A1 
expression with ARID2 knockdown in the PBRM1 shRNA #2 cells (Figure 4.18C).  In the A-704 EV line, 
ARID2 knockdown likewise decreased ALDH1A1 protein expression, but not as completely as in the 786-
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O shRNA lines (Figure 4.18D).  Again, ARID2 knockdown in cells expressing PBRM1 (the A-704 WT line) 
led to loss of PBRM1 expression, demonstrating that even exogenously expressed PBRM1 requires 
ARID2 for stability. 
 
Figure 4.14 – BETA analysis of H3K4Me3 and H3K4Me1 changes and differential 
expression.  BETA analysis as in Figure 4.11 for changes in the histone marks H3K4Me3 (A) 
and H3K4Me1 (B).  The gained or lost peak files generated from the bdgdiff analysis of 
histone mark binding in the 786-O lines were used separately for the binding region inputs.  




Figure 4.15 – BETA 
analysis of H3K27Ac, 
H3K27Me3, and 
H3K9Ac changes and 
differential expression.  
BETA analysis as in 
Figure 4.11 for changes 
in the histone marks 
H3K27Ac (A), 
H3K27Me3 (B), and 
H3K9Ac (C).  The 
gained or lost peak files 
generated from the 
bdgdiff analysis of 
histone mark binding in 
the 786-O lines were 
used separately for the 
binding region inputs.  
There was only 1 gained 
H3K9Ac peaks, so BETA 





Figure 4.16 – BETA-identified direct gene targets with histone mark changes 
in H3K4Me3 and H3K4Me1 and differential gene expression.  The top 40 
BETA-identified direct gene targets that gain H3K4Me3 peaks and have 
upregulated or downregulated expression or lose H3K4Me1 and have 
downregulated expression. The genes are ordered by the rank product, which 







Figure 4.17 – H3K4Me3 binding patterns at specific loci.  H3K4Me3 binding enrichment levels (compared to 
input DNA) around the TSS of specific genes, as visualized on the UCSC genome browser.  For a specific gene, the 
scales of binding enrichment have been set equal to each other across all lines.  H3K4Me3 binding around the 
























 ARID2 is required for tumorsphere formation but not cell viability 
We next tested whether ARID2 knockdown had any functional consequences.  We knocked down 
ARID2 in the 786-O control and PBRM1 shRNA #2 cells, and then checked their tumorsphere-forming 
capacity (Figure 4.19).  As seen previously, the PBRM1 shRNA cells formed significantly more 
tumorspheres than the controls cells when transfected with control siRNA.  With ARID2 knockdown, the 
tumorsphere-forming capacity significantly declined for both cells lines.  The results resembled the effects 
of knocking down or inhibiting ALDH1A1. 
 We wondered whether ARID2 knockdown inhibited tumorsphere formation due to reduced cell 
viability or growth rates.  Synthetic lethal relationships have been found between some SWI/SNF 
components, such as BRG1 and BRM, or ARID1A and ARID1B.  However, that does not appear to be the  
Figure 4.18 - ALDH1A1 upregulation with PBRM1 deficiency requires ARID2.  A.) Western blot 
analysis exploring effects of knocking down ARID2 in the 786-O control or PBRM1 shRNA #1 lines.  A non-
targeting siRNA was used as a control (C); siRNAs #6, #7, and #9 targeted ARID2. B.) qRT-PCR analysis 
of ALDH1A1 mRNA levels (relative to GAPDH) in the indicated cell lines with ARID2 knockdown.  Error 
bars represent standard deviations for n=3.  The delta-delta-Ct method was used to analyze the data, with 
786-O control shRNA and C siRNA set to 1.  An ordinary one-way ANOVA correcting for multiple 
comparisons comparing the C siRNA to the ARID2 siRNAs in each line were performed.  C.) Western blot 
analysis exploring effects of knocking down ARID2 in the 786-O control or PBRM1 shRNA #2 lines.  D.) 
Western blot analysis exploring effects of knocking down ARID2 in the A-704 EV and WT lines.   
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case for PBRM1 and ARID2, although ARID2 knockdown did slow growth and reduce cell viability 
somewhat (Figure 4.20A and B).  However, even with ARID2 knockdown, the cells still grew, and the 
large majority were viable, with only a 10-20% reduction in viability compared to the control siRNA 
transfected cells.  These differences are unlikely to account for the large drop in tumorsphere-forming 
capacity.  
 
SNF5, BRG1, and BRM appear dispensable for ALDH1A1 upregulation with PBRM1 deficiency 
 We next tested whether other SWI/SNF subunits found in the PBAF complex were required for 
ALDH1A1 upregulation with PBRM1 deficiency.  Employing the same strategy as we did for ARID2, we 
knocked down SNF5 or BRG1 with siRNA in 786-O control and PBRM1 shRNA #1 cells (Figure 4.21A 
and B, respectively).  It appeared that we achieved good levels of knockdown of both proteins.  However, 
unlike for ARID2, SNF5 and BRG1 seemed dispensable for the high levels of ALDH1A1 expression in the 
PBRM1 knockdown line.  In the control cells, the low levels of ALDH1A1 were still reduced with SNF5 or 
BRG1 knockdown.  Additionally, PBRM1 stability did not seem as dependent on SNF5 or BRG1.  With 
SNF5 knockdown, PBRM1 levels were reduced in the control cells, but not to the same degree as seen 
with ARID2 knockdown.  BRG1 knockdown did not impact PBRM1 levels in the control cells. 
Figure 4.19 – ARID2 is required for tumorsphere formation.  A.) Tumorsphere assays 
in 786-O control and PBRM1 shRNA #2 lines.  Cells were transfected with non-targeting 
siRNA (C) or ARID2-targting siRNAs (#7 or #9) 24hrs before plating for tumorsphere 
assay.  n=3-6/condition; unpaired t-tests were used for statistical testing. B.) Western blot 
analysis of ARID2 expression levels in same cells used for tumorsphere assay with ARID2 




Figure 4.20 – ARID2 knockdown has only minor effects on cell growth and viability.  786-O 
control and PBRM1 shRNA #2 cells were plated on wells of 6-well plates, and transfected with the 
indicated siRNA (NC=non-targeting siRNA; and “mock” transfected cells received no siRNA).  At the 
indicated timepoints, cells were trypsinized, resuspended in the presence of trypan blue, and then 
viable and non-viable (trypan blue positive) cells were counted.  The cell counts were used to 
generate the total number of live cells (A) and cell viability (B) measures. 
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We also performed the SNF5 knockdown in the A-704 EV and WT lines (Figure 4.21E).  As 
before, we achieved good levels of knockdown in both lines.  In the A-704 EV cells, SNF5 knockdown led 
to an increase in ALDH1A1 expression.  In the WT cells, no ALDH1A1 expression was detectable, and 
SNF5 knockdown slightly reduced PBRM1 levels.   
 Although the ATPase subunit BRM has not previously been reported to bind in a complex with 
ARID2, in light of the seeming dispensability of BRG1, we wondered whether a subunit switch of BRM for 
BRG1 was occurring with PBRM1 deficiency.  We tested this by knocking down BRM in the 786-O lines, 
but again saw no changes in ALDH1A1 expression levels in the PBRM1 shRNA cells (Figure 4.21C).  To 
see if either ATPase subunit was required, we also performed the double-knockdown of BRM and BRG1, 
but still saw no changes in ALDH1A1 expression in the PBRM1 knockdown line (Figure 4.21D).   
As BRG1 knockdown did not affect ALDH1A1 protein levels in the PBRM1 shRNA cells, we next 
tested how BRG1 knockdown impacted tumorsphere-forming capacity.  Mirroring the effects on ALDH1A1 
protein levels, BRG1 knockdown did not significantly alter tumorsphere formation in the PBRM1 shRNA 
cells (Figure 4.22A).  In the control cells, BRG1 siRNA #1 also had no impact, although siRNA #5 caused 
increased tumorsphere formation.   
In total, these findings suggest a specific requirement for ARID2 for increased ALDH1A1 
expression in the PBRM1 deficient setting, perhaps acting outside of a traditional SWI/SNF complex or 
activity.  More work is needed to fully elucidate ARID2’s role in this setting. 
 
ARID2 is also required for increased EGFR protein levels, but not for decreased IFI27 mRNA levels, seen 
with PBRM1 knockdown  
 To see if the requirement for ARID2 extended beyond ALDH1A1 upregulation, we also tested the 
effects of ARID2 knockdown on total EGFR protein levels, which were increased with PBRM1 deficiency, 
and IFI27 mRNA levels, which were decreased.  Like we saw for ALDH1A1, siRNA knockdown of ARID2 
in the PBRM1 shRNA line led to reduced total EGFR protein, down to a level comparable to the control 
cells (Figure 4.23A).  Additionally, SNF5 or BRG1 knockdown in the PBRM1 shRNA cells had very little 
impact on EGFR levels, again suggesting their dispensability to some of the pro-tumorigenic changes 
associated with PBRM1 deficiency (Figure 4.23B and C).   
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However, ARID2 knockdown did not affect the decreased IFI27 mRNA levels in the PBRM1 
shRNA cells – they remained at similarly low levels (Figure 4.23D).  In the control cells, ARID2 
knockdown led to significant decreases in IFI27 levels, although not to levels comparable to those seen in 
PBRM1 shRNA cells.  This finding, along with the ARID2 ChIP-seq results, suggests that different 
mechanisms may underlie PBRM1-associated transcriptional changes.   
 
Figure 4.21 - SNF5, BRG1, and BRM appear dispensable for ALDH1A1 upregulation with PBRM1 deficiency.  
A.) Western blot analysis exploring effects of knocking down SNF5 in the 786-O control or PBRM1 shRNA #1 lines.  
A non-targeting siRNA was used as a control (“C”); siRNAs #1 and #2 targeted SNF5. B.) Western blot analysis 
exploring effects of knocking down BRG1 in the 786-O control or PBRM1 shRNA #1 lines.  siRNAs #1 and #5 
targeted BRG1. C.) Western blot analysis exploring effects of knocking down BRM in the 786-O control or PBRM1 
shRNA #1 lines.  siRNAs #1, #2, and #5 targeted BRM.  D.) Western blot analysis exploring effects of dual knock 
down of BRM and BRG1 in the 786-O control or PBRM1 shRNA #1 lines.  BRM1 siRNA #5 and BRG1 siRNA #5 




Figure 4.22 – BRG1 is not required for tumorsphere formation.  A.) Tumorsphere assays in 
786-O control and PBRM1 shRNA #2 lines.  Cells were transfected with non-targeting siRNA (C) or 
BRG1-targting siRNAs (#1 or #5) 24hrs before plating for tumorsphere assay.  n=3/condition; 
unpaired t-tests were used for statistical testing. B.) Western blot analysis of BRG1 expression 
levels in same cells used for tumorsphere assay with BRG1 siRNA knockdown at time of plating.   
Figure 4.23 - ARID2 is also required for increased EGFR 
protein levels, but not for decreased IFI27 mRNA levels, seen 
with PBRM1 knockdown. A.) Western blot analysis exploring 
effects of knocking down ARID2 in the 786-O control or PBRM1 
shRNA #1 lines.  A non-targeting siRNA was used as a control 
(“C”); siRNAs #7 and #9 targeted ARID2. B.) Western blot analysis 
exploring effects of knocking down SNF5 in the 786-O control or 
PBRM1 shRNA #1 lines.  siRNAs #1 and #2 targeted SNF5. C.) 
Western blot analysis exploring effects of knocking down BRG1 in 
the 786-O control or PBRM1 shRNA #1 lines.  siRNAs #1 and #5 
targeted BRG1. D.) qRT-PCR analysis of IFI27 mRNA levels 
(relative to GAPDH) in the indicated cell lines with ARID2 
knockdown.  Error bars represent standard deviations for n=3.  The 
delta-delta-Ct method was used to analyze the data, with 786-O 
control shRNA and C siRNA set to 1.  An ordinary one-way 
ANOVA correcting for multiple comparisons comparing the C 




 In this chapter, we explored the mechanisms by which PBRM1 deficiency leads to pro-
tumorigenic transcriptional changes.  We first considered how PBRM1 deficiency would affect the larger 
PBAF complex.  We found that with PBRM1 knockdown in the 786-O and ACHN lines, ARID2 protein 
levels increased, while expression of WT, but not cancer-associated mutant, PBRM1 in the A-704 line 
lowered ARID2 levels (Figure 4.1).  These changes were at least partly due to increased transcription of 
ARID2 in the 786-O and A-704 cells, and PBRM1 mutant primary tumors also had increased ARID2 
mRNA (Figure 4.2).   
 Immunoprecipitation experiments revealed that ARID2 was still capable of binding to other 
SWI/SNF components (BRG1 and SNF5) without PBRM1 (Figure 4.3), confirming previous reports (Yan 
et al., 2005).  As this did not preclude the possibility that some ARID2 was binding outside of SWI/SNF 
with PBRM1 deficiency, we also performed glycerol gradient fractionation of the 786-O lines (Figure 4.4).  
In the control cells, the majority of ARID2 and PBRM1 eluted in the heaviest fractions, separate from 
BRG1 and SNF5 elution, and thus presumably outside of the SWI/SNF complex.  This is in line with a 
previous study of SWI/SNF fractionation patterns in mouse brain nuclear extracts that also found most of 
the PBRM1 eluting apart in the heaviest fractions (Lessard et al., 2007).  The authors conjectured that the 
PBRM1 in these fractions could be part of the mitotic machinery, as PBRM1 had previously been found to 
localize to the kinetochore during mitosis (Xue et al., 2000).  In our cells, with PBRM1 knockdown, we 
saw a shift in the ARID2 elution pattern away from these heavy fractions and more into lighter fractions 
also containing BRG1 and SNF5, but not into other fractions free of BRG1 and SNF5.  The findings thus 
far suggest that PBRM1 deficiency is compensated by increased ARID2 expression and possibly 
increased ARID2 association with SWI/SNF components. 
 As the IP and glycerol gradient fractionation experiments included only the soluble part of nuclear 
extracts, we also conducted cellular fractionation experiments to see if ARID2 cellular localization was 
altered with PBRM1 knockdown (Figure 4.5).  We saw no ARID2, or other SWI/SNF components, in the 
cytosol in any line.  With PBRM1 knockdown, we saw ARID2 levels increase in both the soluble and 
insoluble nuclear fractions.  However, we were not able to detect BRG1 in the insoluble nuclear fraction in 
any cell line, and SNF5 localization here seemed to decrease with PBRM1 knockdown (more so in the 
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PBRM1 shRNA #2 line).  These findings do not invalidate the IP and glycerol gradient results, but suggest 
that more ARID2 may also transit to the insoluble nuclear fraction, perhaps outside of the SWI/SNF 
complex, in the absence of PBRM1.   
 Based on its domain structure, and because it is one of the defining subunits of the PBAF 
complex, PBRM1 is thought to help “target” the complex in the genome.  This theory, however, has never 
been tested.  Because ARID2 is also a PBAF-specific subunit, and at least some fraction of it still binds to 
SWI/SNF components after PBRM1 knockdown, ARID2 ChIP-seq with or without PBRM1 would help 
determine PBRM1’s role in targeting.  Our ARID2 ChIP-seq results suggest that PBRM1 does indeed 
help target PBAF binding in the genome.  With PBRM1 knockdown, we saw a general decline in ARID2 
binding to the genome (Figures 4.6 and 4.7).  Moreover, clustering analysis indicated broad shifts in 
ARID2 binding patterns without PBRM1 (Figure 4.8).  We also saw very little overlap in the binding 
patterns between the two PBRM1 shRNA lines, suggesting some degree of randomness to ARID2 
binding without PBRM1 (Figures 4.7, 4.9).  These findings may also be explained by technical failures of 
the ARID2 ChIP-seq in the PBRM1 shRNA lines, but we do not believe this to be the case.  The shifts in 
binding patterns compared to the control were present in both shRNA lines, de novo clustering analysis in 
both these lines displayed patterns of binding, and gain or loss of ARID2 peaks in both shRNA lines 
significantly correlated with gene expression changes (Figure 4.11). 
 We found that ARID2 binding changes with PBRM1 knockdown were related to gene expression 
changes from our earlier RNA-seq analysis.  For the top upregulated genes, the average ARID2 binding 
profile revealed a peak immediately upstream of the TSS in the control cells that was diminished or lost 
with PBRM1 knockdown (Figure 4.10).  For the most downregulated genes, there was an ARID2 peak 
immediately upstream of the TSS and a wider plateau of binding downstream of the TES in the control 
cells; both these features were largely lost in the PBRM1 knockdown lines.  We also saw an association 
between ARID2 binding changes and differential gene expression using the program BETA.  BETA 
analysis indicated that both loss and gain of ARID2 binding altered gene transcription, and that ARID2 
binding could both activate and repress genes (Figure 4.11).  BETA analysis identified ALDH1A1 as a 
direct gene target with loss of ARID2 binding and increased gene expression with PBRM1 knockdown, 
although it was not among the top 50 genes identified.  Among the top genes inferred as direct targets, 
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we saw EGFL7, CA2, ID1, and JAG1, again implicating PBRM1 in the regulation of various cancer-
related genes and pathways (Figure 4.12). 
 We also explored how PBRM1 knockdown altered the histone landscape.  We saw a widespread 
increase in H3K4Me3 peaks with PBRM1 knockdown in the 786-O cells (Table 4.2).  BETA analysis 
indicated that these gains were highly associated with differential gene expression, and identified 
numerous cancer-associated genes that gained H3K4Me3 peaks and were upregulated, including CA2, 
ID1, JAG1, and ALDH1A1 (Figure 4.14-4.17).  Further studies are needed to determine whether this a 
general mechanism of tumor promotion associated with PBRM1 deficiency.  For example, 
methyltransferases such as MLL1 that methylate H3K4 could be perturbed in the PBRM1 deficient setting 
and changes in growth or tumorsphere formation could be investigated.  Alternatively, one could perturb 
the H3K4Me3 demethylases (KDM5A-C) and observe the resultant changes in growth and gene 
expression.  It is interesting to note that KDM5C (also known as JARID1C) is mutated in ~5% of ccRCC 
cases, and its knockdown in 786-O has been associated with increased tumorigenic potential (Dalgliesh 
et al., 2010) (Niu et al., 2012).  Confirmation of these findings in other cells lines is also needed.   
 Interestingly, we saw very few changes in H3K27Me3 peaks and no association with differential 
gene expression.  This suggests that the antagonism seen between EZH2 and SWI/SNF subunits in other 
cancer types may not extend to PBRM1 in ccRCC. 
In the last section of this chapter, we found that ARID2 was required for some of the pro-
tumorigenic changes we previously associated with PBRM1 deficiency, such as the upregulation of 
ALDH1A1 and EGFR (Figures 4.18 and 4.23), while it wasn’t needed for IFI27 downregulation.  These 
data, along with the ARID2 ChIP-seq results, suggests that different mechanisms may underlie PBRM1-
associated transcriptional changes.  For some genes, such as ALDH1A1 and EGFR, in the presence of 
PBRM1, ARID2 binding in the vicinity of the gene locus is inhibitory.  With the loss of PBRM1, ARID2 
binding around the gene is altered, and is now activating.  In this setting, ARID2 is now required for 
continued upregulation.  For other genes with differential expression, such as ARID2 and IFI27, ARID2 
doesn’t seem to bind in the vicinity with or without PBRM1.  Additionally, ARID2 is not required for 
differential expression, at least for IFI27 downregulation.  These findings could be explained by an indirect 
method of transcriptional regulation.  For yet other genes, such as ID1, JAG1, and EGFL7, the ARID2 
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ChIP-seq suggests yet another mode of regulation.  When PBRM1 is present, ARID2 binds at the TSS 
and gene expression is repressed.  When PBRM1 is lost, ARID2 binding is also lost, and expression 
increases.  It will be interesting to see whether expression of these genes is ARID2 dependent. 
Unlike ARID2, SNF5 and BRG1 seemed dispensable for the ALDH1A1 and EGFR upregulation 
seen with PBRM1 deficiency (Figure 4.18 and 4.23).  There are a few possible explanations for why other 
SWI/SNF subunits may not be required for differential gene expression of genes that require ARID2.  For 
example, after PBAF-complex relocation after PBRM1 loss, nucleosome remodeling could initially be 
required, but after establishing a new context for transcription, could then become dispensable, except for 
continued ARID2 binding.  Alternatively, ARID2 could be acting in a more novel, uncharacterized manner.  
In light of our histone ChIP-seq results, one novel function could be ARID2-specific recruitment or 
exclusion of histone modifying enzymes, outside of nucleosome remodeling.  These results could also be 
explained by ineffective knockdown of SNF5 and BRG1 that we were unable to detect by Western Blot – 

















In this research study, we investigated the mechanisms of tumor suppression by PBRM1 in clear 
cell renal cell carcinoma (ccRCC).  PBRM1, a defining subunit of the PBAF type of SWI/SNF complex, is 
mutated in a variety of cancers, including in ~40% of ccRCCs, making it the second most highly mutated 
gene in ccRCC (behind VHL).  Although many recent studies have looked at how other SWI/SNF 
components function in cancer control, relatively little is known about the tumor suppressive mechanisms 
of PBRM1 in ccRCC.   
 We first found that PBRM1 deficiency enhanced the tumorigenic potential of cells.  These growth 
advantages, however, were only clearly apparent when the cells were grown under stressful conditions, 
such as reduced serum or a 3-D culture environment.  Future studies of PBRM1 tumor suppressor 
functions, and the evaluation of therapies for targeting PBRM1-mutant cells, should bear this in mind. 
 By comparing gene expression differences in ccRCC cell lines and murine embryonic fibroblasts 
(MEFs) with or without PBRM1, we discovered that PBRM1 regulated numerous cancer-related genes 
and pathways.  Recent studies of other SWI/SNF subunits and other classes of epigenetic modifiers have 
come to similar conclusions.  PBRM1 mutation in cancer would thus be expected to have wide-ranging 
effects on a cell, and the targeting of any one specific downstream pathway might have limited efficacy. 
 We decided to further investigate PBRM1 regulation of ALDH1A1 expression.  Numerous studies 
have identified ALDH1A1 as a marker of tumor-initiating cells, although it is unclear if ALDH1A1 actually 
promotes tumorigenicity and how it does so.  Not much has been known about the regulation of 
ALDH1A1 expression in cancer, although recent studies have posited upregulation by β-catenin or 
smad4-mediated repression in prostate cancer cells (Cojoc et al., 2015) (Hoshino et al., 2015).  Another 
study has described inhibition of ALDH1A1 by post-translational acetylation in breast cancer cells, which 
is reversed by SIRT2 action downstream of NOTCH signaling (Zhao et al., 2014).  Our results indicate a 
novel method of regulation.  We found that PBRM1 deficiency led to ALDH1A1 upregulation in numerous 
ccRCC cell lines and MEFs, and PBRM1 mutation in primary tumors was associated with higher 
ALDH1A1 levels.  Additionally, our results suggest that ALDH1A1 is more than just a marker of tumor-
initiating cells, but can increase the tumorigenic potential of cells.  Inhibiting ALDH1A1 or knocking it 
down in the context of PBRM1 deficiency reduced anchorage-independent growth, while over-expressing 
it in the PBRM1-normal setting increased tumorsphere-forming capacity.   
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We additionally explored PBRM1 regulation of the EGFR and IFN pathways.  PBRM1 acted to 
decrease total EGFR protein levels and dampen downstream signaling.  These changes had functional 
consequences, as PBRM1 deficient cells grew faster in response to EGF stimulation, but did not create a 
setting of oncogenic addiction, as PBRM1 deficient cells were also more resistant to EGFR inhibition.  
Alternatively, PBRM1 deficiency reduced basal and IFNα-induced levels of IFI27, a pro-apoptotic 
interferon response gene, and made cells more resistant to growth inhibition by IFNα.  These findings 
suggest that EGFR inhibition, which has largely been abandoned as a therapeutic option for metastatic 
ccRCC due to lack of superiority over IFNα treatment, and IFNα therapy itself might have better clinical 
outcomes in non-PBRM1 mutant tumors.  Previously, ccRCC patients have not been routinely classified 
based on molecular genetic criteria, although recent efforts suggest that this might be where the field is 
headed.   
Finally, we investigated the molecular mechanisms of how PBRM1 deficiency could alter 
transcription, keeping in mind that it is one subunit of the larger PBAF complex.  In agreement with 
previous reports, we found that ARID2 was expressed and still bound to other SWI/SNF components in 
the absence of PBRM1.  In fact, in our ccRCC cell lines, we found that ARID2 mRNA and protein levels 
increased with PBRM1 deficiency, and that more ARID2 may associate with BRG1 and SNF after PBRM1 
knockdown.  ARID2 ChIP-seq in these cell lines suggested that the remnant PBAF-like complex was 
bound to fewer locations in the genome, and was broadly redistributed where it did bind.  As has been 
previously speculated, PBRM1 did indeed seem to function as a “targeting” subunit of PBAF.  Both 
increased and decreased ARID2 binding was associated with differential gene expression, of both 
upregulated and downregulated genes, suggesting that the genomic context influences whether PBAF-
binding is activating or repressive.  Interestingly, we also found that ARID2 was required for some of the 
pro-tumorigenic changes associated with PBRM1 deficiency, such as upregulated ALDH1A1 and EGFR 
levels, but not others, such as decreased IFI27 levels.  Further investigation is needed to determine which 
gene expression changes are ARID2-dependent, and what may be determining this dependency. 
Based on these findings, and looking at patterns of ARID2 binding at specific loci, we propose 
two models by which PBRM1 deficiency could lead to transcriptional changes (Figure 5.1).  For some 
genes, such as ALDH1A1 and EGFR, when PBRM1 is present, PBAF binds in the vicinity of the gene 
99 
 
and dampens transcription (Figure 5.1A).  With PBRM1 deficiency, ARID2 still binds in a PBAF-like 
complex, but binding around the gene is altered, and is now activating.  In this setting, ARID2 is now 
required for continued upregulation, potentially acting through novel mechanisms, such as the recruitment 
of activating co-factors.  For other genes, such as ID1, JAG1, and EGFL7, we propose another mode of 
regulation (Figure 5.1B).  When PBRM1 is present, PBAF binds at the TSS and gene expression is 
repressed.  When PBRM1 is lost, ARID2 binding around the gene is also lost, and expression 
subsequently increases.  It will be interesting to see if differential expression of genes fitting this model of 
regulation is ARID2 dependent.  For yet other genes with differential expression, such as ARID2 and 
IFI27, ARID2 doesn’t seem to bind in the vicinity with or without PBRM1.  Additionally, ARID2 is not 
required for differential expression, at least for IFI27 downregulation.  These findings could be explained 
by an indirect method of transcriptional regulation.   
ChIP-seq of various histone marks also indicated that the active promoter mark H3K4Me3 is 
increasing across the genome with PBRM1 deficiency, and that these increases are highly associated 
with differential gene expression.  Further studies are needed to determine whether this a general 
mechanism of tumor promotion associated with PBRM1 deficiency, and also how these gains are 
associated with ARID2 differential binding. 
Figure 5.1 – Proposed models of how PBRM1 deficiency leads to transcriptional changes. The PBAF 
complex is illustrated as follows: PBAF-specific components PBRM1, ARID2, and BRD7 are colored red; core 
SWI/SNF components BRG1, SNF5, BAF155, and BAF170 are colored blue; and the rest of the complex is 
colored grey.  PBAF components whose association in the complex were inferred from prior reports but were not 
directly verified by co-IP are shaded translucently. 
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While we have identified some novel cancer-related genes and pathways regulated by PBRM1, 
we believe PBRM1 exerts wide effects on transcription and other important PBRM1-regulated genes have 
yet to be characterized.  Moreover, much future work can be done to verify and expand upon the models 
of transcriptional control we are proposing.  We were unable to successfully perform ChIP-seq analysis of 
PBRM1 – doing so will greatly aid in the discovery and verification of genes directly regulated by PBRM1.  
This analysis could also be compared to our ARID2 ChIP-seq results.  ChIP-seq analysis of other 
SWI/SNF components, such as BRG1 or SNF5, can also help determine if a PBAF-like complex is truly 
being redirected with PBRM1 deficiency, or if it is just ARID2.  Lastly, verification of our findings in other 
ccRCC cell lines, and potentially other lineages of cancer, will help establish the veracity of our proposed 
models of PBRM1 transcriptional control.  Ultimately, we hope that a better understanding of the 








MATERIALS AND METHODS 
 
Cell lines 
 786-O, A-704, and ACHN cell lines were purchased from the ATCC.  Murine embryonic 
fibroblasts (MEFs) were generated from PBRM1 fl/fl mice using standard protocols.  Normal culturing 
conditions for each cell line were as follows: 786-O - RPMI 1640 medium supplemented with 10% (v/v) 
fetal bovine serum (FBS), 100 IU penicillin, and 100ug/mL streptomycin (Cellgro); A-704 and ACHN – 
MEM (Cellgro) supplemented with 10% FBS, 100 IU penicillin, and 100ug/mL streptomycin; MEFs – 
DMEM (Cellgro) supplemented with 10% FBS, 1mM glutamine, 100 IU penicillin, and 100ug/mL 
streptomycin.  For reduced serum growth, the cells were washed 2x with PBS, and then switched to the 
appropriate culture media with reduced FBS % (v/v).  When treated with EGF (Peprotech), the cells were 
starved for 16 hours (hr) in the appropriate media without FBS before treatment.  IFNα was purchased 
from Sigma (#SRP4596), erlotinib was purchased from Fisher (#50-148-625), and DEAB (dissolved in 
95% ethanol) provided in the ALDEFLUOR kit (STEMCELL) was used. 
 
Generation of PBRM1 fl/fl mice 
 In collaboration with the Transgenic Mouse Core at Columbia University, we designed a bacterial 
artificial chromosome in which a LoxP site and a Frt-Neo-Frt-LoxP cassette were engineered to flank 
exon 2 of the PBRM1 allele, such that Cre-mediated recombination would result in a frame-shifting 
mutation.  A gene-targeting vector was then constructed with a 2kb short homology arm, a 5kb long 
homology arm, and a DTA negative selection marker.  This vector was transfected into KV1 (129B6 
hybrid) ES cells, which were then selected for recombination with G418.  Two of the positively selected 
ES cells were then injected into C57BL/6 blastocysts to generate chimeric male mice.  Mice that were 
positive for germline transmission of the modified allele were bred to homozygous ACTB (Flpe/Flpe) 
females (in a C57BL/6 background) to remove the Neo cassette.  Heterozygous mice (fl/+) derived from 




Plasmids and constructs 
Full-length PBRM1 was cloned into a pBABEpuro vector as previously described (Xia et al., 
2008).   A C-terminal V5 tag was added to this plasmid using site-directed mutagenesis, and this plasmid 
was then used as a template to make the PBRM1 cancer mutants. The ALDH1A1-HA vector in pcDNA 
was purchased from Addgene (#11610) and was produced by the Steven Johnson lab.  
 
Mutagenesis 
The QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) was used. Primers were designed 
using the Agilent website for site-directed mutagenesis and are listed below. Clones were sequenced to 
confirm the presence of the engineered mutations and the absence of secondary mutations. 
Table 6.1: PCR Site Directed Mutagenesis Primers: 
Mutant Primer 
PBRM1 T232P Forward: 5'-cctatagatctcaagcccattgcccagaggata-3' 
Reverse: 5'-tatcctctgggcaatgggcttgagatctataggct-3' 
PBRM1 A597D Forward: 5'-gctgatgttccggaatgacaggcactataatgagg-3' 
Reverse: 5'-cctcattatagtgcctgtcattccggaacatcagc-3' 
PBRM1 H1204P Forward: 5'-acatttttgtgggctcaggctctgtttcttcaggg-3' 
Reverse: 5'-ccctgaagaaacagagcctgagcccacaaaaatgt-3' 
PBRM1 Ile57del Forward: 5'-gccatgaactctataatacccgagactataaggatgaaca-3' 
Reverse: 5'-tgttcatccttatagtctcgggtattatagagttcatggc-3' 
PBRM1 1204 6AA del Forward: 5'-cagagcatgagcccacaaaagtatttctgagtaatctgga-3' 
Reverse: 5'-tccagattactcagaaatacttttgtgggctcatgctctg-3' 
 
Transfection and infection 
Transfections were done using Lipofectamine 2000 (Invitrogen). Retrovirus was produced by 
transfection of pBABE constructs into the Phoenix HEK-293 packaging cell line (Swift et al., 2001). 
Transduced A-704 cells were selected in 2ug/mL puromycin for 10-14 days. 
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 For PBRM1 knockdown experiments, MISSION Lentiviral Transduction Particles were purchased 
from Sigma-Aldrich (clone IDs: TRCN0000235890 and TRCN0000015994) and used according to the 
manufacturer’s instructions. Briefly, 1x105 (786-O) or 2x105 (ACHN) cells were transduced with the viral 
particles at a MOI = 3, along with a final concentration of 12 μg/mL polybrene. 786-O cells were selected 
with 3 μg/mL puromycin, and ACHN cells with 1 μg/mL puromycin, for 10-14 days.  Non-targeting control 
shRNA (Sigma, SHC016) lentiviruses were produced in HEK-293T cells (Lois et al., 2002). 
 At passage 2, MEFs were infected with either control GFP adenovirus (Vector Biolabs, #1060) or 
Cre adenovirus (Vector Biolabs, #1045) in 6-well plates.  MEFs were passaged 3 times, and then mRNA 
was collected for microarray and qRT-PCR analysis, protein was collected, and growth curve analysis 
was performed. 
For siRNA knockdown experiments, siRNA sets were purchased from Qiagen: ALDH1A1 – 
GS216; ARID2 - GS196528; BRG1 - GS6597; SNF5 - GS6598; BRM - GS6595. The indicated siRNAs 
from each set were used for experiments.  Sigma MISSION siRNA Universal Negative Control #1 
(SIC001) was used as negative control siRNA.  
 
Immunoblotting 
Protein lysates from cell lines was were collected by scraping the tissue culture plate with 2X 
Sample Buffer (125mMTris-HCl pH 6.8, 4% SDS, 20% glycerol, 0.05% Bromophenol Blue, 8M urea, and 
10% BME added fresh), subjecting the lysates to 5x 1 second bursts of sonication, boiling for 5 minutes 
(min), and then centrifuging at 14,000 rpm for 5 min at 4⁰C. Samples were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) on Tris-Glycine precast gels (Invitrogen) and then 
transferred to PVDF membrane using wet transfer methods. After probing with primary and secondary 









The following antibodies were used (Table 6.2):  
Protein 
Target Purpose Company Catalogue # Type 
Concentratio
n 
















Biotechnology sc-8749 (N-15) goat polyclonal 1:500 
BRG1 IP 
Santa Cruz 
Biotechnology sc-17796 (G-7) 
mouse 
monoclonal 3ug per IP 





Biotechnology sc-6450 (N-19) goat polyclonal 1:500 










Technology 5605 (D84C12) 
rabbit 
monoclonal 1:1000 
Lamin B1 WB 
ThermoFisher 
Scientific 33-2000 (L-5) 
mouse 
monoclonal 1:1000 
Actin WB Sigma-Aldrich A4700 
mouse 
monoclonal 1:40000 















































affinity gel IP Sigma-Aldrich A7345 
mouse 
monoclonal 50ul per IP 
H3K4Me3 ChIP-seq Abcam ab8580 
rabbit 
polyclonal 3ug/ChIP 
H3K4Me1 ChIP-seq Abcam ab8895 
rabbit 
polyclonal 3ug/ChIP 





H3K27Ac ChIP-seq Millipore 07-360 
rabbit 
polyclonal 3ug/ChIP 




* PBRM1 polyclonal antibodies were generated against a glutathione S-transferase fusion protein of a C-
terminal PBRM1 fragment (amino acids 736–1,475). 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
Total RNA was prepared using the Qiagen RNeasy kit.  Approximately 1 ug of RNA was used to 
generate cDNA using Superscript Reverse Transcriptase II (Invitrogen). qRT-PCR was performed in an 
ABI 7500 machine, using Fast SYBR Green (Invitrogen) according to the manufacturer’s instructions. The 
primer sequences were as follows: PBRM1 forward, 5′- TGGAACCTGCAGAGGCCAACC -3′, and 
reverse, 5′- TTTTCACCAGCTGAATCCTCCCACA -3′; ALDH1A1 forward, 5′- 
TTGGAAGATAGGGCCTGCAC -3′, and reverse, 5′- GGAGGAAACCCTGCCTCTTTT -3′; IFI27 forward, 
5′- ATCAGCAGTGACCAGTGTGG -3′, and reverse, 5′- GGCCACAACTCCTCCAATCA -3′; ARID2 
forward, 5′- TACTTGCTAATGCCGGGGTG -3′, and reverse, 5′- ACGATGTCTTTCCAAAACTTAACGA -3′; 
GAPDH forward, 5′-GAAGGTGAAGGTCGGAGTCAAC-3′, and reverse, 5′-
CAGAGTTAAAAGCAGCCCTGGT-3′.  Samples were run in triplicate. The efficiencies of the primers were 
measured using standard curves and were calculated to be: PBRM1 – 2.00; ALDH1A1 – 2.03; IFI27 – 
1.99; ARID2 – 1.98; and GAPDH – 2.00. Quantitative analysis was performed on the basis of the ΔΔCt 
method using the housekeeping gene GAPDH.  
 
Nuclear extraction 
 Nuclear extraction was performed on 786-O and A-704 cells prior to the immunoprecipitation and 
glycerol gradient experiments.  For each cell line, 5 15cm plates (80-90% confluent) were collected at 
once.  Each plate was washed 2x in cold PBS, and then was collected by scraping into cold PBS 
containing protease inhibitors (Sigma, P8340).  Cells were spun at 700xg at 4⁰C for 5 min.  The pellet was 
then resuspended by pipetting and vortexing in 3.5mL of cold Buffer A (10mM HEPES-KOH pH 7.9, 
10mM KCl, 0.1mM EDTA, 0.1mM EGTA), supplemented with fresh dithiothreitol (DTT) at 1mM and 
protease inhibitors.  After 5 min, 10% Triton X-100 in Buffer A (pre-made) was added 1:20 to a final 
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concentration of 0.5%, and the sample was vortexed again.  After another 5 min, the sample was 
centrifuged at 1000xg at 4⁰C for 5 min.  The pellet (nuclei) was then washed once by resuspending in 
1mL of cold Buffer D (20mM HEPES-KOH pH 7.9, 1mM EDTA, 1mM EGTA), supplemented with fresh 
1mM DTT and protease inhibitors.  The sample was centrifuged again at 1000xg at 4⁰C for 5 min, and the 
pellet was now resuspended in 0.5mL of cold Buffer C (20mM HEPES-KOH pH 7.9, 400mM NaCl, 1mM 
EDTA, 1mM EGTA), supplemented with fresh 1mM DTT, protease inhibitors, and 1mM sodium 
orthovanadate.  The sample was vortexed, passed numerous times through a 18.5G syringe, and then 
incubated on ice for 5 min.  10% Triton X-100 in Buffer C (pre-made) was added 1:20 to a final 
concentration of 0.5%, and the sample was again vortexed, passed numerous times through a 18.5G 
syringe, and then incubated on ice for 5 min.  The sample was then centrifuged at 14,000 rpm at 4⁰C for 
10 min.  The supernatant (nuclear extract) was removed, and the extraction was repeated on the pellet, 
beginning with resuspension in 0.5mL of Buffer C.  The second nuclear fraction was then combined with 
the first, and then 0.6 volumes of cold Buffer D, supplemented with fresh 1mM DTT and protease 
inhibitors, was added to lower the solute concentration.  The nuclear extract was then filtered through a 
0.22um filter using a 1mL syringe, a small aliquot was set aside to quantify the protein concentration 
using the Bradford protein assay, and the nuclear extract was snap frozen and stored at -80⁰C. 
 
Immunoprecipitation 
Immunoprecipitation (IP) experiments were performed on isolated nuclear extracts.  0.5mg of 
total protein was diluted to 1mL total volume using cold Buffer C/D (1.0:0.6 ratio), supplemented with 
fresh 1mM DTT, protease inhibitors, and 1mM sodium orthovanadate.  For each BRG1 IP, 3ug of BRG1 
antibody (G-7) or mouse IgG (as a control) (Santa Cruz, #sc-2025) was prebound to 30ul Protein G 
Dynabeads (ThermoFisher) by nutating for 2-4 hr at 4⁰C in PBS plus 0.02% Tween-20.  The beads were 
then washed once in 200ul PBS plus 0.02% Tween-20, and then resuspended in 30ul cold Buffer C/D, 
supplemented with fresh 1mM DTT, protease inhibitors, and 1mM sodium orthovanadate for use in the IP 
reaction. 
The nuclear extract was pre-cleared using 30ul Protein G Dynabeads and nutating for 1hr at 4⁰C.  
An aliquot to serve as the input control was removed (10ul), and then the sample was divided in two for 
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incubation with BRG1-bound beads or control IgG-bound beads.  The samples were nutated overnight at 
4⁰C, and then using a magnet the magnetic beads were washed 4x with 1mL cold Buffer C/D, 
supplemented with fresh 1mM DTT, protease inhibitors, and 1mM sodium orthovanadate.  For the last 
wash, the resuspended beads were moved to a fresh tube.  After the last wash, the beads were 
resuspended in 60ul of 2X sample buffer, boiled for 5min, and then the sample was placed back on the 
magnet and the sample buffer supernatant was transferred to a fresh tube and subjected to Western blot 
analysis. 
The V5 IP experiments in the A-704 lines were performed similarly, except 50ul V5-agarose 
affinity gel was used for the IP, and 50ul of protein A/G agarose beads (Santa Cruz, #sc-2003)) and 4ug 
mouse IgG was used for the pre-clear.  Beads were isolated during the wash steps by centrifuging at 
200xg for 3 min at 4⁰C. 
 
Growth curve analysis 
Experiments were carried out in 48-well plates at least in triplicate (see figure legends for n-sizes 
for individual experiments). For 786-O and ACHN, 4 × 103 cells were plated per well, for A-704, 6 × 103 
cells were plated per well, and for MEFs, 2 × 103 cells were plated per well.  At the indicated time 
intervals, cells were washed once with PBS, stained with 0.05% crystal violet in formalin at room 
temperature for 20–30 min, and washed again twice with PBS before extracting the dye with 10% acetic 
acid.  Plates were shaken on a microplate shaker at medium speed for at least 1hr, and the absorbance 
(O.D.), corresponding to cell numbers attached on the plates, was measured at 595 nm on a multi-well 
plate reader (Bio-Rad).  
Alternatively, cell growth in some experiments was monitored using the IncuCyte live cell imaging 
system (Essen BioScience), which was placed in a cell culture incubator operated at 37°C and 5% CO2. 
Cell confluence was determined using calculations derived from phase-contrast images. 
 
Colony formation in soft-agar 
 1 × 104 cells were used per plate, and experiments were performed on all samples in triplicate.  
Agar (Difco) was resuspended to 3% (w/v) in PBS and sterilized.  1mL of agar diluted to 0.5% in the 
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appropriate culture media (warm) was aliquoted into a 35mm plate as a support layer, which was then 
allowed to dry in the 37°C incubator.  Healthy-looking cells were then trypsinized and counted, 
appropriate cell numbers were spun down, and then resuspended in warm media to a single-cell 
suspension.  When drug treatments were used (e.g., DEAB, erlotinib), they were mixed into the media at 
this stage.  The liquid 3% agar (kept warm at 60⁰C in a heat block) was added moderately quickly to the 
cell mixture to a final concentration of 0.3%, the solution was thoroughly mixed, and then 1mL of the 
cell:agar solution was layered onto the support layer (creating a single, uniform layer without agar 
chunks).  The agar plates were placed into larger plates containing some sterile water to prevent the 
plates from drying out, and then were placed in the 37°C incubator to allow colonies to form for 23 days, 
with careful monitoring every 3-4 days. 
To quantify colony formation, the cells were stained with 1mL of 0.005% crystal violet solution in 
formalin for 1 hr.  The staining solution was carefully removed, and then the plates were scanned and 
colonies quantified using ImageJ software (with a minimum colony size cut-off of 10 pixels). 
 
Xenografts 
 Cells used for xenograft experiments had been split a few days prior to use and were healthy 
looking and still growing.  2 hr prior to injection, the cells were re-fed.  They were then trypsinized, 
counted, washed in media, resuspended in cold media, and then combined 1:1 with cold Matrigel 
(Trevigen) to a concentration of 1x106 per 0.2mL and kept on ice.  6 week-old female athymic nude mice 
were subcutaneously injected on their ventral flanks with 1x106 control and PBRM1 shRNA cells (opposite 
flanks of the same mouse – total of 4 mice).  Tumor xenograft growth was monitored, and after the tumors 
were palpable (10 days), size was measured using calipers (length and width measurements were taken, 
and volume calculated using the formula: (length x width2)/2).  When tumor size exceeded the limitations 
specified by IACUC (>1000mm3), the mice were euthanized.  All mice were treated humanely according 
to the guidelines established by IACUC. 
 After euthanasia, tumors were harvested and weighed.  For Western blot analysis, small sections 
were excised and placed in 500ul of cold RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% 
NaDeoxycholate, 150 mM NaCl, 1 mM EDTA), supplemented with fresh protease inhibitors, in pre-chilled 
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12x75mm borosilicate glass tubes.  The excised xenografts were then homogenized for ~10 seconds, 
until no chunks were visible.  The mixture was then sonicated 5x with 1 second bursts, and was allowed 
to sit on ice for 30 min, vortexing every 5 min.  The solution was transferred to Eppendorf tubes, spun at 
4⁰C for 20 min at maximum speed, the supernatant was transferred to a new tube, and then the spin step 
was repeated.  The supernatant was again transferred to a fresh tube, and was subjected to the Bradford 




 The ALDEFLUOR assay kit was purchased from STEMCELL Technologies, and the 
manufacturer’s instructions were followed.  Briefly, cells that were ~80% confluent were trypsinized, 
washed in PBS, and resuspended in the provided Assay Buffer, and then counted.  2x105 cells in 0.5mL 
Assay Buffer were used per reaction, and 2.5ul of substrate per reaction was used for the 786-O cells, 
and 5ul per reaction for the A-704 cells.  The chemical inhibitor DEAB was added to the recommended 
concentration of 15uM to the negative control sample before adding the substrate to set the negative 
baseline of no enzyme activity.  The cells were incubated with substrate for 40 min at 37⁰C, were 
centrifuged and then resuspended in 0.5mL cold Assay Buffer, and kept on ice in the dark until 
fluorescence was measured using a BD LSRFortessa cell analyzer and FACSDiva software.  ALDH1-
activity was calculated by gating on live, single cells, establishing a negative baseline using the DEAB-
treated sample, and then measuring the % of cells that were positive for ALDH1-activity by green 
fluorescence levels on the x-axis.  This analysis was done using Cytobank. 
 
Tumorsphere Assay 
 The tumorsphere assay described herein was derived from published protocols (Shaw et al., 
2012) (Ueda et al., 2013).  Healthy-looking, growing cells were trypsinized, counted, and washed in 
tumorsphere media (appropriate cell culture medium, penicillin, streptomycin, 1x B-27 Supplement 
(Gibco, #17504-044), 20ng/mL EGF, and 20ng/mL bFGF (R&D, #233-FB-025)).  Cells were then 
resuspended to single-cell suspensions in tumorsphere media, and 4 x103 cells in 3mL were plated into 
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wells of ultra-low attachment 6-well plates (Costar, #3741).  When drug treatments were added, they were 
added to the single-cell suspensions with mixing before plating.  Tumorsphere formation was quantified 
after 3.5 days using phase contrast images at 100x of all cells in a well, and then analyzing the images 
with ImageJ software.  A grouping of cells was counted as a tumorsphere if it was >50um in diameter, 
and represented a solid mass of cells, with indistinguishable cell borders. 
 To measure tumorsphere self-renewal, the tumorspheres were passaged at this point.  All the 
media was collected from a well, the cells were briefly spun down, and then resuspended in tumorsphere 
media and counted.  Cells were re-plated as before at roughly the same starting density (4 x103 cells in 
3mL) – if the total cell count for a well was less than 6 x103 cells, all the cells went back into a single well, 
but if the cell count was higher, the cells were divided into 2 wells.  When tumorsphere formation was 
quantified for these cells, tumorspheres from cells that had been divided between two wells were added 
together (see (Shaw et al., 2012)). 
 For siRNA experiments, cells were transfected with the indicated siRNA for 24 hr before they 
were plated for the tumorsphere assay.  For the ALDH1A1 overexpression experiment, the cells were 
transfected for 36 hr prior to plating.  Extra cells that were not plated were spun down, combined with 2X 




 Cells were collected from a 10cm plate at ~80% confluence by scraping into cold PBS 
supplemented with fresh protease inhibitors.  The cells were pelleted by centrifuging at 700xg at 4⁰C for 5 
min, and were washed twice with cold PBS plus protease inhibitors.  The cells were lysed by adding 
300ul of Buffer A (10 mM HEPES, pH 7.4, 10mM KCl, 100uM EDTA), supplemented with fresh protease 
inhibitors and 1mM DTT.  The cells were placed on ice for 15 min, and then 10% NP40 in Buffer A (pre-
made) was added 1:20 to a final concentration of 0.5%, the sample was vortexed for 5 seconds, and then 
nutated at 4⁰C for 2 min.  The sample was then centrifuged at 1000xg at 4⁰C for 5 min, and 200ul of the 
supernatant was carefully taken from the top and stored as the cytoplasmic fraction.  The rest of the 
supernatant was removed, and the pellet consisting of the nuclei was resuspended in 100ul Buffer C (20 
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mM HEPES, pH 7.4, 400mM NaCl, 1mM EDTA), supplemented with fresh protease inhibitors and 1mM 
DTT.  The sample was taped to a vortexer and vortexed at moderate speed (setting just below 6) for 15 
min at 4⁰C.  The sample was then centrifuged at top speed at 4⁰C for 15 min to collect the supernatant as 
the soluble nuclear fraction.  The pellet was the insoluble nuclear fraction.  To resuspend it, 40ul of 2X 
sample buffer was added, the sample was vortexed vigorously, sonicated 5x with 1 second bursts, boiled 
for 15 min, and then centrifuged again at top speed at 4⁰C for 5 min.  The supernatant was run on a gel 
as the insoluble nuclear fraction.  For the other fractions, 2X sample buffer was added 1:1, the samples 
were boiled for 5 min, and then were ready for SDS-PAGE. 
 
Glycerol gradient fractionation 
 Glycerol gradients were made using 10% and 30% glycerol solutions, to a total volume of 11.5 
mL per gradient, using a dual piston gradient maker (Jule, J17) and 13.2mL thin-wall polypropylene tubes 
(Beckman Coulter, 14x89mm, #331372).  Glycerol solutions were made by diluting glycerol (v/v) into 
Buffer C/D (1.0:0.6), supplemented with fresh 1mM DTT, protease inhibitors, and 1mM sodium 
orthovanadate.  The fractionation was performed on isolated nuclear extracts diluted to a final 
concentration of 1.7mg/mL in cold Buffer C/D (1.0:0.6), supplemented with fresh 1mM DTT, protease 
inhibitors, and 1mM sodium orthovanadate.  0.5 mL of the diluted nuclear extract was carefully layered on 
top of the glycerol gradient.  The gradients were spun for 18 hr in a TH-640 swinging bucket rotor at 
40,700 rpm at 4⁰C in an ultracentrifuge.  ~0.5mL fractions (9 drops) were collected from the bottom 
(heavier fractions) of the tube (24 fractions total).  Aliquots of the fractions were combined with 2X sample 
buffer and subjected to Western blot analysis.   
 
RNA-seq 
 Before RNA was collected, cells were passaged and grown at the specified serum levels for 48 
hr.  When RNA was collected, the cells were ~70% confluent and healthy-looking.  Total RNA was 
collected using the Qiagen RNeasy kit.  Poly-A selection of mRNA, RNA-seq library preparation, and 
100bp single-end sequencing using an Illumina HiSeq machine was performed by the Genomics Core 
Facility at the Icahn Institute and Department of Genetics and Genomic Sciences.  FastQC checks were 
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performed on the raw data, and then the Tuxedo suite of tools was used to align the reads to 
GRCh37/hg19 and check for differential expression following the protocol outlined in Trapnell et al., 2012 
(Trapnell et al., 2012).  Downstream processing and analysis was performed as described in the text. 
 
Microarray expression analysis 
 After infection with adenovirus, MEFs were passaged 3 times, and then total RNA was collected 
for microarray analysis using the Qiagen RNeasy kit.  The Ambion WT Expression Kit (#4411973) was 
used to generate amplified sense-strand cDNA, and fragmentation and labeling was performed with the 
GeneChip WT Terminal Labeling and Controls Kit (Affymetrix, #901525).  Microarray expression analysis 
was performed using GeneChip Mouse Gene 2.0 ST Arrays (Affymetrix, #902118) following the 
manufacturer’s instructions.   
 
ARID2 ChIP-seq  
Cell fixation and sonication 
 786-O cells were grown to ~80% confluency on 15cm plates, the media was replaced with 10mL 
cold PBS, and the cells were cross-linked with 1% formaldehyde (Pierce, #28908) for 5 min at 4⁰C with 
gentle rocking.  The fixation was stopped by the addition of glycine, the plates were washed 2x with cold 
PBS, and then the fixed cells were collected into cold PBS supplemented with fresh protease inhibitors.  
The output from 3-5 plates were pooled (enough to generate >18x106 fixed cells – 1 extra plate was set 
aside to count and passage the cells).  The cells were collected by centrifuging at 700xg for 5 min at 4⁰C, 
and the pellets were snap frozen and stored at -80⁰C for less than two weeks. 
 To sonicate, the cell pellets were thawed on ice, and then were prepared for sonication using the 
TruChIP Chromatin Shearing Reagant Kit (Covaris, # PN 520154) following the manufacturer’s 
instructions.  3x106 cells in 130ul of D3 buffer (Covaris kit) were loaded into Covaris AFA microtubes, and 
the cells were sonicated for 3.5 min on a Covaris M220 focused ultrasonicator (5% duty factor, 75W peak 
incident power, 200 cycles/burst, 7°C).  This level of sonication preserved the ARID2 epitope (as shown 
by Western blot), and yielded chromatin ranging in size from 100-1000bp, with a peak around 500-700bp 
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(evaluated using Agilent Bioanalyzer 2100).  For each cell line, 6 aliquots of cells were sonicated, and the 
sonicated chromatin was pooled. 
 
ChIP 
 Each sample was centrifuged at maximum speed for 20 min at 4⁰C, and a volume of supernatant 
equivalent to 15x106 cells was transferred to a new tube.  The total volume was raised to 1mL using cold 
D3 buffer, and NaCl was added to raise the total salt concentration to 140mM.  The sample was pre-
cleared by adding 30ul of Magna ChIP Protein A+G Magnetic Beads (Millipore, #16-663) and nutating at 
4⁰C for 20 min.  The beads were removed, and 10ul (1%) of the sample was removed and stored at -80⁰C 
as the input DNA. To the rest of the sample, 5ug of ARID2 (E-3) antibody was added, and the 
immunoprecipitation was carried out for 4 hr at 4⁰C.  50ul of Magna beads were then added, and a further 
2 hr incubation at 4⁰C was carried out. 
 The magnetic beads were then isolated using a magnet, the unbound chromatin was removed, 
and the beads were washed for 5 min in 1mL of each of the following buffers: Low salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 150mM NaCl); High salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM NaCl); LiCl wash buffer (0.25M LiCl, 
1% deoxycholate, 1% NP40, 1mM EDTA, 10mM Tris-HCl, pH 8.1); and two washes in TE buffer (10mM 
Tris-HCl, pH 8.1, 1mM EDTA).  For the last wash, the beads were moved to a new tube.  After the last 
wash, the wash buffer was removed and the beads were stored at -80⁰C overnight.   
Beads were thawed, and precipitated chromatin was eluted in 150ul of elution buffer (1% SDS, 
0.1M sodium bicarbonate) by shaking on a Thermomixer for 15 min at 37⁰C.  This process was repeated 
on the beads, and the eluted chromatin was pooled to 300ul.  At this point, input DNA was thawed, and 
the total volume was also brought up to 300ul using elution buffer.  To reverse crosslinks, 12ul of 5M 
NaCl was added, and the sample was incubated for 4 hr at 65°C. The sample was then treated with 
RNase for 30 min at 37⁰C, and proteinase K for 2 hr at 45°C.  DNA was extracted via phenol/chloroform 
followed by DNA purification using Qiagen MiniElute PCR purification tubes.  The amount and size of the 
precipitated DNA was evaluated using the Bioanalyzer. 
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To generate enough DNA to make ChIP-seq libraries for sequencing, we repeated the entire 
process on a different batch of cells for each cell line.  The precipitated DNA was then pooled for each 
cell line (ARID2-associated DNA from 30x106 cells total). 
 
ChIP-seq library preparation and sequencing 
 ChIP-seq libraries were made following well-established protocols (see Hasson et al., 2013) 
(Hasson et al., 2013).  Briefly, 2-10ng of DNA was end-repaired, an A-overhang was added, Illumina 
Truseq adapters were ligated, DNA was run on an agarose gel and size-selected at 350-500bp using the 
Qiagen Gel Extraction Kit, and finally libraries were PCR amplified for 10-14 cycles using KAPA 
Biosystems HiFi PCR Master Mix.  Where not indicated, all library preparation steps involved New 
England Biolabs enzymes.  The quality and concentration of the prepared libraries were assessed on the 
Bioanalyzer - the libraries produced U-shaped DNA profiles, with an average peak around 400bp.  75bp 
single-end sequencing was performed on an Illumina NextSeq 500 machine.  
 
ChIP-seq data processing and analysis 
FastQC was run on the ChIP-seq raw data for quality control.  Bowtie 2 was used to align reads 
to the genome (GRCh37/hg19).  The following settings were used (if not specified, the default settings 
were applied): a seed length of 75 was used, a maximum of 2 mismatches were allowed, only uniquely 
aligning reads were used, and the --best option was selected. After aligning, ENCODE-defined blacklisted 
regions of the genome were removed. 
 SICER-df was used for ARID2 peak-calling and differential peak identification with the following 
options: genome build – hg19; effective genome size – 0.793; redundancy threshold – 2; window size – 
200; fragment size – 400; gap size – 600; and an FDR threshold of less than 0.05 for both peak and 
differential peak identification.  Input DNA was used as the control sample for each cell line.  ARID2 
enrichment levels were also generated using SICER, comparing the ARID2 signal to the input DNA.  
HOMER’s annotatePeaks was used for genomic annotation.  Galaxy’s deepTools was used to look at the 
average enrichment profiles at specified regions and for clustering analysis.  The genomic location of 
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specific genes was defined according to the human hg19 (GRCh37.p13) gene annotation of Ensembl 
(gene database version 75), and was provided by the lab of Emily Bernstein.   
 
Native ChIP-seq of histone marks 
 Native ChIP-seq was performed according to the detailed procedures outlined in Hasson et al., 
2013 (Hasson et al., 2013).  Briefly, 20-50x106 cells were swelled and lysed using 0.1% IGEPAL, nuclei 
were collected by centrifugation through a sucrose gradient, and micrococcal nuclease digestion was 
optimized for each cell collection to primarily generate mononucleosomes, without overdigesting.   
For the ChIP step, 3ug of each histone mark antibody was used, and 50ug of chromatin was used 
for methyl marks, and 100ug was used for acetyl marks.  The cells were precleared as for ARID2 (and 
input DNA was collected), and the antibody incubation was performed overnight.  50ul of Magna beads 
were then added, and a further 3 hr incubation at 4⁰C was carried out.  Bead washing, processing of input 
DNA, and extraction and purification of DNA was performed as in Hasson et al., 2013.   
ChIP-seq libraries were prepared as described above, with the following changes: DNA was size 
selected from between 300-400bp on the agarose gel to exclude polynucleosomes, which produced 
amplified libraries with sharp peaks of ~280bp, as seen on the Bioanalyzer.  Sequencing and ChIP-seq 
data processing was performed as before.  MACS2 was used for peak-calling, with the options --nomodel 
--extsize 150, and with default q-value cutoffs (<0.01), except for the H3K27Me3, where the --broad 
option was selected and the default q-value threshold is 0.1.  For use in bdgdiff, the SPMR option was not 
selected, but to generate pileups, it was turned on.  The MACS2 tool bdgdiff was used with default 
parameters.  Pileups were generated using MACS2 for the default enrichment value (histone mark signal 
over input DNA). 
 
Statistical analysis 
All statistical analysis was performed on GraphPad Prism 6 software. Statistical tests used for specific 
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